GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
Phase: PHASE1
Conditions: SBRT, NSCLC, Non-metastatic
Sponsor: Galera Therapeutics, Inc.

 
 
 
CLINICAL STUDY PROTOCOL 
 
Protocol Title: 
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study 
of Stereotactic Body Radiation Therapy (SBRT) and GC4711 
for Centrally Located or Large, Node-Negative Non-Small Cell 
Lung Cancer (NSCLC) 
Protocol Number: 
GTI-4711-101 
Compound: 
GC4711 
Sponsor 
Sponsor 
Name: 
Galera Therapeutics Inc. 
Legal 
Registered 
Address: 
2 West Liberty Blvd, Suite 110, Malvern, PA 19355 
Regulatory Agency 
Identifier Number(s) 
150,818 
Protocol Date: 
Document Version 
Date 
Original (v 0.0) 
08June2020 
Amendment 01 
07July2020 
Amendment 02 
09July2020 
Amendment 02.1 
(Administrative update) 
10July2020 
Amendment 3.0 
03February2021 
Amendment 4.0 
18April2022 
 
 
 
 
 
 
 
 
 
CONFIDENTIALITY NOTICE 
The information contained in this protocol and all other information relevant to GC4711 are the 
confidential and proprietary information of Galera Therapeutics Inc. and, except as may be 
required by federal, state, or local laws or regulation, may not be disclosed to others without the 
prior written permission of Galera Therapeutics Inc. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 2 of 71 
 
 
Study Acknowledgement 
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation 
Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell 
Lung Cancer (NSCLC) 
This protocol has been approved by Galera Therapeutics, Inc. The following signature 
documents this approval. 
 
Jon Holmlund, MD 
Chief Medical Officer 
Galera Therapeutics, Inc. 
 
Investigator Statement 
I have read the attached protocol and agree to abide by all provisions set forth therein. I will 
provide copies of the protocol and other pertinent information to all individuals responsible to 
me who will assist with the study. 
I agree to comply with the International Conference on Harmonization, Tripartite Guideline on 
Good Clinical Practice (ICH, GCP) in accordance with local government and applicable global 
and local government regulations/guidelines, for example, including 21 Code of Federal 
Regulations (CFR) Parts 11, 50, 54, 56, and 312. 
I agree to ensure that Financial Disclosure Statements will be completed before study initiation, 
during the studies if there are changes that affect my financial disclosure status, and one year 
after study completion by: 
· 
myself (including, if applicable, my spouse [or legal partner] and dependent children) 
· 
my sub-investigators (including, if applicable, their spouses [or legal partners] and 
dependent children) 
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Galera Therapeutics. 
The Sponsor or its designee will have access to source documentation from which case report 
forms have been completed. 
 
 
 
Signature of Principal Investigator 
Date (DD MMM YYYY) 
 
 
 
Printed Name of Principal Investigator 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 3 of 71 
 
 
TABLE OF CONTENTS 
1 
SYNOPSIS ................................................................................................................................... 6 
2 
INTRODUCTION ....................................................................................................................... 16 
2.1 
Radiotherapy for Non-Small Cell Lung Cancer ................................................................... 16 
2.2 
Investigational Medicinal Product ...................................................................................... 18 
2.2.1 GC4711 Nonclinical Data .................................................................................................... 18 
Figure 1 GC4711 Potentiated the Antitumor Effects of SBRT in a Human NSCLC Model .............. 19 
2.2.2 GC4711 Clinical Data .......................................................................................................... 21 
2.3 
GC4711 Benefit/Risk Assessment ...................................................................................... 22 
3 
OBJECTIVES AND ENDPOINTS ................................................................................................. 23 
4 
STUDY DESIGN......................................................................................................................... 25 
4.1 
Overall Design .................................................................................................................... 25 
4.2 
Study Duration for Participants .......................................................................................... 26 
4.3 
Number of Participants ...................................................................................................... 27 
4.4 
Replacement of Participants .............................................................................................. 27 
4.5 
Number of Sites .................................................................................................................. 27 
4.6 
End of Study Definition....................................................................................................... 27 
4.7 
Rationale for Study Design ................................................................................................. 27 
4.8 
Rationale for GC4711 Starting Dose ................................................................................... 28 
5 
SELECTION AND WITHDRAWAL OF SUBJECTS ........................................................................ 29 
5.1 
Inclusion Criteria ................................................................................................................ 29 
Figure 2 Anatomy of central and ultra-central lung tumors .......................................................... 30 
5.2 
Exclusion Criteria ................................................................................................................ 30 
5.3 
Screen Failures ................................................................................................................... 31 
5.4 
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ............................................................................................ 31 
6 
INVESTIGATIONAL PRODUCT AND TREATMENT OF SUBJECTS ............................................... 32 
6.1 
Investigational Product: GC4711/Placebo ......................................................................... 32 
GC4711 Dosage Formulation and Preparation .................................................................. 32 
GC4711 Dosage, Administration, and Schedule ................................................................. 32 
GC4711 Drug Packaging and Labeling ................................................................................ 33 
Maintenance of the Blind .............................................................................................. 33 
Investigational Product Storage and Accountability ...................................................... 33 
Study Intervention Compliance ..................................................................................... 34 
6.2 
Stereotactic Body Radiation Therapy (SBRT) ..................................................................... 34 
SBRT Dosage, Administration, and Schedule ..................................................................... 34 
Critical Organ Dose-Volume Limits .................................................................................... 36 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 4 of 71 
 
 
6.1 
Collection of Concomitant Medications ............................................................................. 37 
6.2 
Drug Interactions ................................................................................................................ 38 
6.3 
Prohibited Medications ...................................................................................................... 39 
6.4 
Toxicity Management and Infusion Modification .............................................................. 39 
Anticipated toxicities of GC4711 ........................................................................................ 39 
Toxicity Management/Infusion Modifications ................................................................... 40 
Anticipated toxicities of SBRT ............................................................................................. 40 
7 
STUDY ASSESSMENTS AND PROCEDURES ............................................................................... 41 
7.1 
Efficacy Assessments .......................................................................................................... 42 
Tumor Assessment (RECIST) ............................................................................................... 42 
Definitions for Response Evaluation .................................................................................. 43 
7.1 
Safety Assessments ............................................................................................................ 43 
7.2 
Adverse Events and Serious Adverse Events...................................................................... 45 
Time Period and Frequency for Collecting Adverse Events and Serious Adverse 
Events Information ............................................................................................................. 46 
Method of Detecting Adverse Events and Serious Adverse Events ................................... 46 
Follow-up of Adverse Events and Serious Adverse Events ................................................ 46 
Regulatory Reporting Requirements for Serious Adverse Events ...................................... 47 
Treatment of Overdose, Misuse, Abuse ............................................................................. 47 
7.3 
Pregnancy ........................................................................................................................... 47 
7.4 
Late Radiotherapy Toxicities .............................................................................................. 48 
7.5 
Phase 1 Dose-limiting Toxicities ......................................................................................... 48 
7.6 
Pharmacokinetics (PK) and ECG ......................................................................................... 49 
8 
STATISTICAL CONSIDERATIONS ............................................................................................... 49 
8.1 
Sample size ......................................................................................................................... 49 
8.2 
Randomization/Blinding ..................................................................................................... 49 
8.3 
Populations for Analyses .................................................................................................... 50 
8.4 
Subject Disposition ............................................................................................................. 50 
8.5 
Statistical Analyses ............................................................................................................. 51 
Primary Endpoints: .......................................................................................................... 51 
Secondary Efficacy Endpoints: ........................................................................................ 51 
Exploratory Endpoints ..................................................................................................... 52 
8.6 
Safety Review Committee (SRC) ......................................................................................... 52 
8.7 
Interim Analysis .................................................................................................................. 52 
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations .......................................... 53 
Regulatory and Ethical Considerations ............................................................................ 53 
Financial Disclosure ......................................................................................................... 53 
Informed Consent Process .............................................................................................. 54 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 5 of 71 
 
 
Data Protection ............................................................................................................... 54 
Data Quality Assurance ................................................................................................... 54 
Source Documents .......................................................................................................... 55 
Study and Site Start and Closure ..................................................................................... 55 
Publication Policy ............................................................................................................ 55 
Appendix 2: Clinical Laboratory Tests ............................................................................................ 57 
Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ................................................................................................ 58 
Definition of Adverse Event............................................................................................. 58 
Definition of Serious Adverse Event ................................................................................ 59 
Recording and Follow-Up of Adverse Events and/or Serious Adverse Events ................ 60 
Reporting of SAEs ............................................................................................................ 61 
Appendix 4: Relationship Between National Cancer Institute – Common Terminology 
Criteria for Adverse Events, Version 5.0 and Radiographic Pneumonitis/Fibrosis 
Criteria (Kimura IJROB 2006) ........................................................................................... 62 
Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information ........................... 63 
Appendix 6: Abbreviations ............................................................................................................. 65 
Appendix 7: References .................................................................................................................. 67 
Table 1 
Schedule of Activities ............................................................................................ 14 
Table 2 
Organ Constrains for a 3-Fraction SBRT Regimen ................................................. 34 
Table 3 
Organ Constrains for a 5-Fraction SBRT Regimen ................................................. 35 
Table 4 
CYP2D6-substrate drugs ........................................................................................ 38 
Table 5 
Expected acute and late SBRT toxicities summarized ........................................... 41 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 6 of 71 
 
 
1 SYNOPSIS 
 
Name of Sponsor/Company: 
Galera Therapeutics, Inc. 
Name of Investigational Product: 
GC4711 
Title of Study: 
Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy 
(SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung 
Cancer (NSCLC) 
Number of Study Center(s): Phase 1: Approximately 4 centers in the United States 
Phase 2: Up to 20 centers in the United States 
Estimated Enrollment Period: ~36 months 
Studied period (years): 
First patient enrolled, Phase 1: Q4 2020 
Last patient completed, Phase 1: Q3 2021 
First patient enrolled, Phase 2: Q3 2021 
Estimated date last patient completed, Phase 2: Q3 2023 
Phase of development: 1-2 
Objectives: Phase I 
Primary: To assess the safety of GC4711 administered intravenously (IV) in combination with 
5 fractions of stereotactic body radiation therapy (SBRT) in subjects with Non-Small Cell Lung 
Cancer (NSCLC) 
Secondary: To evaluate the efficacy, and acute and late toxicities of GC4711 + 3 or 5 fractions 
of SBRT 
Objectives: Phase II 
Primary: To determine the percentage of patients with complete or partial in-field tumor 
response based on the RECIST 1.1 criteria through 6 months following completion of SBRT 
Secondary: 
• To determine the best in-field tumor response at 6-, 12-, 18- and 24-months following 
completion of SBRT 
• To compare progression-free survival, overall survival, local tumor control, and distant 
metastasis rates over a 2-year follow up period for SBRT plus GC4711 or placebo 
• To assess durability of in-field complete or partial responses 
• To determine acute lung toxicity after SBRT + GC4711 compared to SBRT + placebo 
for early-stage NSCLC 
• To evaluate the rate of acute and late radiation toxicities for SBRT + GC4711 compared 
to SBRT + placebo 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 7 of 71 
 
 
 
• To assess the relationship between clinical, functional and radiographical lung function 
changes observed after SBRT 
Exploratory (Phase I and II) 
• To evaluate risk of lung injury, its development pattern over time, and patient/disease 
and dosimetry characteristics in relation to additional GC4711 
• To evaluate the pharmacokinetics of GC4711 in the study population 
• To collect initial information about acute effects of GC4711, including cardiovascular 
events and electrocardiogram parameters 
Rationale: 
GC4711, a novel, water soluble, low molecular weight, manganese-containing macrocyclic 
ligand complex, is being developed as a 15-minute intravenously (IV)-administered treatment 
given in combination with stereotactic body radiotherapy (SBRT; also known as stereotactic 
ablative radiotherapy, or SABR) to improve efficacy and reduce normal tissue damage of high 
dose per fraction radiation delivery in early-stage non-small cell lung cancer (NSCLC). 
The number of patients with limited NSCLC are fast increasing due to screening programs and 
more frequent thoracic imaging in general, but many newly diagnosed patients are not good 
surgical candidates; the combination of SBRT with GC4711 as a safe and efficient alternative 
may be of great value in lung cancer management. 
Modern RT techniques have enabled more precise delivery of high ablative doses with improved 
sparing of surrounding normal tissue. For early-stage NSCLC, SBRT has become an alternative 
to surgery (Timmerman 2010). After initial demonstration of safety with SBRT for small 
peripheral NSCLC lesions, SBRT has been delivered to larger and more central lesions (Bezjak 
2019), which identified SBRT dosing of 11.5 or 12 Gy x 5 fractions as associated with 
acceptable toxicity and with approximate 2-year rates for local control, overall survival, and 
progression-free survival of approximately 90%, 70%, and 55%, respectively. The practice is 
shifting toward 5 fractions specially for central localizations; however, a 3-fraction regimen is 
still accepted. Use of SBRT for larger or centrally located NSCLC is reported to increase the 
risk of toxicity with a larger volume of normal tissue exposure (Fakirs 2009, Woody 2015, 
Peterson 2016, Beak 2019). SBRT can induce inflammatory reactions and sequentially generate 
fibrosis and lung functional restrictions (Lu 2018). Individual risk of radiation-induced 
pneumonitis depends on the volume of lung treated and the radiation dose administered, as well 
as patient age and other treatment modalities used (immunotherapy itself has around 10% 
pneumonitis risk on its own (Zhao 2016, Mohamad 2018)). Central tumors have a higher 
complication risk because of the close relation to the major airways, esophagus, and major 
vessels. These tumors are treated with 5 or more fractions of SBRT (Lo 2009) to give normal 
tissue within the field more time to repair (Timmerman 2006). Radiation induced injury is a 
slowly developing process, developing radiological changes and symptoms around 3-6 months 
(mean 135 days) after treatment (Vide tic 2013, Takeda 2013, Jain 2018, Ferrero 2015). 
Approximately a quarter of patients encounter lung function decline, after a 5-fraction regimen 
SBRT (Stone 2015). A small portion of patients (approximately 10%) remain with a significant 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 8 of 71 
 
 
 
decline in lung function, which can be difficult to distinguish from disease recurrence (Huang 
2012). Radiological changes have been described in a larger number of patients but are not 
always accompanied by clinical symptoms. Historical incidence of functional and radiological 
lung changes is based on a 3 or 6 monthly assessment throughout the first 1-2 years after the 
completion of treatment. For interrelated risk-benefit evaluation, it is key to collect clinical, 
radiological, and functional data at these same time points, thus gathering sufficient clinical 
information over the first 12 months to distinguish patterns. 
The action of GC4711 to convert superoxide to hydrogen peroxide has the potential to be a 
radiosensitizer, increasing both the efficacy and safety of SBRT. In nonclinical models, the 
addition of selective dismutase mimetics to SBRT regimens with or without concomitant 
systemic anti-cancer therapy enhanced tumor control while protecting normal tissues from 
radiation (Sishc 2018). Furthermore, in GC4711 nonclinical pharmacology studies, GC4711 
augmented the anti-tumor activity of SBRT in NSCLC and pancreatic cancer experimental 
xenograft mouse models. 
These observations support conducting a trial of GC4711 to reduce the potential lung toxicity 
of SBRT while possibly improving anti-tumor activity. 
Methodology: 
GTI-4711-101 is a Phase I/II study of the safety of GC4711, its effect on in-field tumor response 
per RECIST 1.1 and its potential to reduce radiation-related pulmonary injury due to SBRT for 
lymph node negative (T1 to T3N0M0) peripheral or central localized (within 2cm of the 
proximal bronchial tree) NSCLC. After an open-label, Phase 1, safety cohort of 5 subjects has 
been completed, a randomized, placebo-controlled Phase 2 portion will be conducted. 
Subjects must be referred for SBRT with large peripheral lesions (>1cm-7cm) and/or central 
localized, node negative, non-metastatic NSCLC, and have an ECOG PS score of 0-3 (Buccheri 
1996) to be considered for enrollment. Subjects with small peripheral lesions (≤1cm) are 
excluded, as the aim is to improve outcome in larger, central NSCLC carrying a higher risk of 
pneumonitis, as well as poorer local control. Feasibility of SBRT is judged by the treating 
physician. 
SBRT is planned for the tumor location as a dose of 5 fractions of 10-12 Gy or 3 fractions of 
18-20 Gy (Phase 2 only). SBRT fractions will be given sequentially, and within 180 minutes 
from the end of the GC4711 or placebo infusion. Between fractions, a minimum of 18 hours 
and a maximum of 96 hours are permitted. All fractions should be given within 10 calendar days 
(+3 days in the case of a holiday or technical issue). 
Phase 1: In the Phase 1 portion, 5 subjects will each receive 100 mg of GC4711 by 15-minute 
IV infusion, before each SBRT fraction, beginning the day of the first fraction and ending the 
last day of SBRT (5 doses in total). SBRT is administered within 180 minutes (3 hours) of the 
end of the GC4711 infusion. 
All 5 subjects will be monitored for dose limiting toxicity (DLT) occurring during treatment 
with SBRT and GC4711 or within 30 days post-therapy. DLT is defined (using the National 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 9 of 71 
 
 
 
Cancer Institute−Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading 
scale) as Grade 3-5 AEs occurring from Day 1 to 30 days post SBRT completion, and excluding 
the following: 
• AEs clearly related to disease progression or intercurrent illness 
• Grade 3 fatigue for 7 days or less, 
• Grade 3 nausea/vomiting or diarrhea for less than 72 hours with adequate antiemetic 
and other supportive care 
• Grade 3 or higher amylase or lipase that is not associated with symptoms or clinical 
manifestations of pancreatitis 
• Hematological grade 3-4 toxicities except for the following: 
o Grade 4 neutropenia lasting >7 days. 
o Grade 3 thrombocytopenia with clinically significant bleeding. 
o Grade 4 anemia and grade 4 thrombocytopenia 
Safety will be judged unacceptable if 2 or more (i.e., no more than one) of the 5 subjects develop 
a DLT. Safety will be reviewed by a Safety Review Committee (SRC) consisting of the Medical 
Monitor, the Principal Investigator from each Phase 1 site, and additional designees by the 
Sponsor or the site Principal Investigators. 
Phase 2: After the SRC has confirmed acceptable safety for Phase 1, a Phase 2, randomized, 
placebo-controlled study will be initiated, wherein approximately 66 subjects referred for SBRT 
with early stage large and/or central localized NSCLC will be randomized in a 1:1 ratio to 
receive either GC4711 100 mg or placebo given intravenously (IV) over 15 minutes before each 
fraction of SBRT, beginning the day of the first fraction of SBRT and ending the last day of 
SBRT. 
The primary endpoint will be the difference in in-field RECIST response rate at 6 months post 
SBRT completion. 
The secondary endpoints will include overall response, pulmonary function, pneumonitis 
assessed clinically and radiographically, and time to event endpoints (PFS, OS, Local and 
Distant Control). 
Detailed information on dose-volume exposure, co-treatment and sensitivity profiles of existing 
obstructive lung disease will be collected for pneumonitis-risk analyses. Pharmacokinetic (PK) 
sampling and cardiac monitoring will be performed on each subject with two separate doses of 
GC4711 (or placebo) collecting blood samples pre-infusion and post-infusion for each. 
Number of Subjects: 
Phase 1: 5 subjects 
Phase 2: Approximately 66 subjects (~33 per arm, GC4711 or placebo) 
Diagnosis and Main Criteria for Inclusion: 
Inclusion Criteria: 
1. Male or female subjects at least 18 years of age. 
2. Ability to understand and the willingness to sign a written informed consent. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 10 of 71 
 
 
 
3. Histological or biopsy proven Non-Small Cell Lung Cancer. For peripheral 
lesions, cytology and/or clear imaging-guided suspicion is accepted if histology 
cannot be obtained. 
4. ECOG performance status of 0-3. 
5. Node negative (T1 to T3N0M0), centrally located (within 2cm in all directions 
around the proximal bronchial tree, including ultra-central tumors, abutting the 
bronchial tree or trachea) or large (>1-7cm) Non-Small Cell Lung Cancer 
(NSCLC), judged acceptable for SBRT by the treating Investigator. Staged with 
FDG-PET/CT, brain CT or MRI with contrast and/or mediastinoscopy, 
measurable disease as defined by RECIST 1.1. 
6. Adequate end-organ function, based on routine clinical and laboratory workup: 
a. ANC >1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 7.0 g/dl 
b. Serum creatinine ≤ 2 mg/dL or calculated creatinine clearance ≥ 30 
ml/min 
c. Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and 
ALT ≤ 2.5 x ULN 
7. Males and females of must agree to use effective contraception starting prior to 
the first day of treatment and continuing after the last dose of GC4711/Placebo 
for 30 days (females) and 90 days (males). 
Exclusion Criteria 
1. Subjects with confirmed nodal and/or distant disease (including brain) using 
standard workup (per investigator). 
2. Subjects with peripheral lesions of 1cm or smaller 
3. Prior treatment with immunotherapy within 3 months prior to Day 1 dosing. 
4. Prior intra-thoracic radiotherapy or surgery with substantial overlap to planned 
radiation fields as determined by the treating radiation oncologist. 
5. Subjects not recovered/controlled from prior treatment-related (chemotherapy or 
targeted therapy) toxicities judged by treating physician. 
6. Uncontrolled malignancy other than lung cancer that requires active treatment or 
is deemed by the treating physicians to be likely to affect the subject's survival 
duration. 
7. History of allergic reactions attributed to compounds of similar chemical or 
biologic composition to GC4711. 
8. Uncontrolled intercurrent illness including, but not limited to, active infection, 
symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that, in the opinion of the 
investigator, would limit compliance with study requirements. 
9. Participation in other clinical trials actively testing new anti-cancer treatments, 
unless previously written approval is provided by the Sponsor. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 11 of 71 
 
 
 
10. Requirement for concurrent treatment with nitrates or other drugs that may, in the 
judgment of the treating investigator, create a risk for a precipitous decrease in 
blood pressure. 
11. Female subjects who are pregnant or breastfeeding. 
12. Any other conditions that, in the Investigator’s opinion, might indicate the 
subject to be unsuitable for the study. 
Duration of Treatment: 
Phase 1: SBRT is administered in 5 sequential fractions of 10-12 Gy with each fraction 
preceded by once daily (QD) doses of GC4711 (5 doses) from the start to the last fraction 
Phase 2: SBRT is administered in 5 sequential fractions of 10-12 Gy or 3 sequential fractions 
of 18-20 Gy with each fraction preceded by once daily (QD) doses of GC4711/placebo (3 or 5 
doses) from the start to the last fraction 
Reference Therapy, Dosage and Mode of Administration: 
Phase 1 will use open-label GC4711 to be given as a 15-minute, 100 mL IV infusion. GC4711 
100 mg QD should be completed within 180 minutes prior to SBRT (5 doses). 
Phase 2 will include two treatment arms: 
- 
Arm A: GC4711 100 mg (15 min, 100 mL IV infusion to complete within 180 
minutes prior to SBRT) administered before each SBRT, from the first dose of SBRT 
to the last fraction of SBRT. 
- 
Arm B: Placebo (15 min, 100 mL normal saline IV infusion) given in combination 
with SBRT as described for Arm A. Normal saline should be provided by the site’s 
unblinded pharmacists. 
SBRT will deliver 5 fractions of 10-12 Gy or 3 fractions of 18-20 Gy to confirmed tumor 
area), no elective fields are given. Between fractions, a minimum of 18 hours and a maximum 
of 96 hours are permitted. All fractions should be given within 10 calendar days (+3 days in 
the case of a holiday or technical issue). 
Criteria for Evaluation: 
- 
NCI-CTCAE version 5.0 for Adverse Events and clinical pneumonitis evaluation 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5 
_Quick_Reference_8.5x11.pdf 
- 
RTOG Pulmonary toxicity scale (Stone 2015) for decline in DLCO 
- 
CT (chest/abdomen/pelvis) evaluation using RECIST 1.1 (Eisenhauer EA 2009) for 
tumor evaluation 
- 
CT (chest) for radiographic evaluation of pneumonitis 
- 
FVC, FEV1, DLCO, SpO2 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 12 of 71 
 
 
 
Safety Monitoring and Toxicity Management: 
Adverse/Serious Adverse Event (AE/SAE) assessments are categorized using CTCAE version 
5.0. Subjects in Phase 1 will be monitored for DLTs as outlined above for 30 days post SBRT 
completion. 
Additionally, all subjects in Phase 1 and Phase 2 will be monitored 90 days post-SBRT for all 
adverse events to evaluate acute toxicities, and monitored for 1-year post-SBRT completion for 
specific late toxicities as defined in Section 7.4 Late Radiotherapy Toxicities. 
Toxicities that will require infusion modification of GC4711 or placebo include the following: 
• Grade 2 or greater hypotension occurring within 1 hour of the end of GC4711 or 
placebo infusion 
• Other Grade 3 or greater AEs judged by the investigator to be possibly attributable to 
the study infusion. 
Patients who experience a toxicity noted above during or shortly after the infusion of 
GC4711/placebo should have their infusion times increased to 30 minutes. 
If the toxicity recurs, the infusion time should be increased to 45 minutes, and may be 
increased to 60 minutes if hypotension occurs with a 45-minute infusion. 
If toxicity occurs with a 60-minute infusion, the patient should be discontinued from further 
treatment with GC4711/placebo but should remain on study for all other protocol interventions 
(SBRT) and assessments. 
Concomitant Medications/Treatments: 
Investigators may prescribe concomitant medication or supportive care deemed necessary. All 
medications taken from 30 days prior to dosing through 90 days post completion of SBRT 
should be documented in source records and in the CRF. 
After 3 months post completion of SBRT, only medications used to treat respiratory disease or 
late radiation toxicities (see section 7.4) should be recorded through 12 Months, including 
inhalers, steroids, oxygen supply, etc. 
Any new anti-cancer therapy given in follow-up should be recorded in the CRF through 24- 
months post-SBRT or until tumor progression has been recorded. 
Supportive care includes antiemetic prophylaxis, hematopoietic growth factor as used per 
ASCO guidelines, systemic antibiotics, hydration to prevent renal damage etc., consistent with 
local standard of practice, with the following exceptions: 
Prohibited medications/treatments: 
- 
Nitrates, phosphodiesterase type 5 (PDE 5) inhibitors (e.g., sildenafil, tadalafil, or similar 
agents) or other drugs that in the judgment of the treating Investigator could create a risk 
of a precipitous decrease in blood pressure are prohibited until at least 24 hours after the 
last dose of GC4711/placebo. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 13 of 71 
 
 
 
- 
Approved or investigational anti-cancer therapy (e.g., chemotherapy, immunotherapy, 
targeted therapy, hormone, and biologic therapy) given during SBRT other than the 
protocol regimen 
Statistical Considerations: 
In Phase 1 portion of the study, 5 subjects will be treated and monitored for DLTs. DLT is 
defined above and in Section 7.5. 
Safety is considered acceptable if no more than one subject experiences a DLT during treatment 
or within the 30-day post-therapy safety observation period. 
In Phase 2, approximately sixty-six (66) participants, randomized 1:1 to GC4711 or placebo, 
will be recruited to achieve 60 evaluable subjects, assuming a 10% drop-out. 
Sample size in Phase 2 is selected to provide a reasonably precise estimate of the treatment 
effect as measured by the width of a two-sided 90% confidence interval around the difference 
in in-field tumor response as well as to provide other efficacy data that can used in planning 
future studies. With 30 patients/arm the half-width of the 90% confidence interval. To 
supplement the routine monitoring outlined in this protocol, a Safety Review Committee (SRC) 
will periodically review safety data and related delays in SBRT administration. See Section 8.6 
for details. 

 
 
 
Table 1 
Schedule of Activities 
 
Procedure 
Screening a 
ACTIVE TREATMENT 
PERIOD 
POST SBRT FOLLOW-UP 
D1 
D2 
D3 
D4 
D5 
D12 or 
Early Term b 
30- and 90-days 
post SBRT c 
M6, 
M12 c 
M18, M24 
Post-SBRT d, 
Informed consent 
X 
Inclusion and exclusion criteria e 
X 
Registration/Randomization 
(Phase 1/Phase 2) e 
X 
Medical history (includes smoking history) 
X 
Demography 
X 
Complete PE including height and weight 
X 
X 
ECOG Performance Status 
X 
X 
Vital signs f 
X 
X 
X 
X 
X 
X 
PK Blood samples g 
X 
X 
12-lead ECG h 
X 
X 
X 
AE/SAE review i 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medications/treatments 
and smoking review j 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Survival Status 
X 
X 
X 
Serum pregnancy test (WOCBP only) 
X 
Serum chemistry panel 
X 
X 
Complete blood count 
X 
X 
X 
PT/INR, aPTT 
X 
PFTs – SpO2, FEV1, FVC and DLCO k, n 
X 
X 
CT chest for pneumonitis scoring k 
X 
X 
X 
CT (chest, abdomen, pelvis) k 
X 
X 
X 
GC4711/Placebo IV infusion l 
X 
X 
X 
Xl 
Xl 
SBRT administration m 
X 
X 
X 
Xm 
Xm 
AE = adverse event, BP = blood pressure, CBC = complete blood count, CT = computed tomography, CTCAE = Common Terminology Criteria for Adverse Events, DLCO = diffusion capacity of lung for 
carbon monoxide, ECG = electrocardiogram, ECOG PS = eastern cooperative oncology group performance status, FEV1 = forced expiratory volume in 1 second, FU = Follow-up, , IV = intravenous, PE = 
physical examination, PET = positron emission tomography, PFTs = pulmonary function tests, PK = pharmacokinetics, SAE = serious adverse event. 

 
Compound: GC4711 
Galera Therapeutics, Inc. 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
 
 
 
 
 
a Screening evaluations should occur within 21 days of Treatment Day 1, except where otherwise noted 
b The Day 12 visit should occur 7 days after the last dose of SBRT ±5 days 
c The 30- and 90- day post SBRT completion visits should occur on or within 7 days after target date and may be performed remotely via telemedicine visits. The Months 6 and 12 post SBRT completion 
visits should occur ±7 days of target date. 
d The Month 18 and 24 post SBRT visits should occur ±14 days of target date. 
e  Registration/Randomization should occur after all screening assessments are performed, eligibility is confirmed, and within 7 days of the first dose of SBRT. Confirmation of eligibility should include 
confirmation of diagnosis, histology and exclusion of distant disease by standard practice. 
f BP and HR should be taken prior to each infusion, monitoring possible hypotensive symptoms, please repeat before going from infusion to radiation site. 
g  PK blood samples should be drawn pre-and post- - infusion on Day 1 and Day 3. The end of infusion PK draw should be drawn within 10 minutes after the end of infusion and the ECG should be +/- 10 
minutes from the PK draw. 
h The ECGs will be collected in triplicate pre- and post-infusion as close to PK draws as possible. The end of infusion PK draw should be drawn within 10 minutes after the end of infusion and the ECG 
should be +/- 10 minutes from the PK draw. A 12-lead ECG recording will be conducted using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF 
intervals. 
i AE/SAE collection will occur through 30 days post SBRT completion for treatment related adverse events, will continue through 90 days post SBRT completion for acute toxicities (all AEs/SAEs) and 1- 
year post SBRT completion for late radiation toxicities. Please see Section 7.4 for the definition of late radiation toxicities. The DLT period is through 30 days post-SBRT for Phase 1 subjects. Please see 
Section 7.5 for details on the DLT definition. 
j All medications taken from 30 days prior to dosing through 90 days post SBRT completion should be documented in source records and CRF. After 90 days post-SBRT, only medications used to treat 
late radiation toxicities should be recorded through 12 Months post SBRT completion, including inhalers, steroids, oxygen supply, etc. Additionally, any new anti-cancer therapy given in follow-up 
should be recorded in the CRF through 24 months post-SBRT or disease progression. 
k Imaging assessments performed as part of standard of care within 56 days of dosing will be accepted. Investigator Response Assessment should follow RECIST 1.1. Suspicion of progression should be 
confirmed with PET at 6 months. Radiographic assessment of pneumonitis will occur by evaluating for presence of descriptors listed in the table in Appendix 4. 
l GC4711 or placebo will be given prior to each dose of SBRT starting the first day of SBRT through the last day of SBRT. GC4711/placebo infusion should be completed within 180 minutes prior to the 
start of SBRT. For patients treated with a 3-fraction SBRT regimen, only 3 doses of GC4711 will be administered. 
m SBRT will be administered within 180 minutes after completion of GC4711/placebo. A minimum of 18 hours and a maximum of 96 hours are permitted between fractions. All fractions should be given 
within 10 calendar days (+5 days in the case of a holiday or technical issue). 
n Pulmonary function testing (PFT) to be conducted at Months 6 and 12 only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 15 of 71 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 16 of 71 
 
 
2 INTRODUCTION 
2.1 
Radiotherapy for Non-Small Cell Lung Cancer 
Lung cancer is the leading cause of death in the United States, with approximately 135,000 
deaths predicted in 2020 (Ettinger 2020). As recently as 2015, the 5-year survival rate for non- 
small cell lung cancer (NSCLC) was 25% (Ettinger 2020). While surgery for early-stage disease 
remains the preferred treatment, advances in noninvasive treatment modalities, such as targeted 
therapy, immunotherapy, and modified forms of radiotherapy (RT), have contributed to 
improved outcomes (Ettinger 2020). Stereotactic body radiotherapy (SBRT; also known as 
stereotactic ablative radiotherapy, or SABR) is an RT regimen that targets tumors with image- 
guided, short dose-intensive ablative courses of radiation, in contrast to conventionally 
fractionated RT (Timmerman 2010). SBRT is a current accepted alternative for surgery of 
peripheral lung lesions (Stephans 2018, Timmerman 2010, Prezzano 2019) and can be an 
alternative for larger or central tumors in a 5-fraction regimen in more fragile patients for whom 
chemo-radiation or surgery presents too great a risk of complications (Peterson 2016, Bezjak 
2019, Ettinger 2020). 
Modern RT techniques have enabled more precise delivery of high ablative doses with improved 
sparing of surrounding normal tissue. For early stage NSCLC, SBRT has become increasingly 
used as standard of care (Timmerman 2018). After initial demonstration of safety with SBRT for 
small peripheral NSCLC lesions, SBRT has been delivered to larger and more central lesions 
(Bezjak 2019), which identified SBRT dosing of 11.5 or 12 Gy x 5 fractions as associated with 
acceptable toxicity and with approximate 2-year rates for local control, overall survival, and 
progression-free survival of approximately 90%, 70%, and 55%, respectively. Use of SBRT for 
larger or centrally located NSCLC is reported to increase the risk of toxicity with a larger volume 
of normal tissue exposure (Fakiris 2009, Woody 2015, Peterson 2016, Bezjak 2019). SBRT can 
induce serious inflammatory reactions depending on dose and volume given to the lung and 
generate fibrosis and lung functional restrictions (Lu 2018). SBRT delivering a Biological 
Equivalent Dose of over 100 Gy to the lung is associated with grade 2 or worse pneumonitis in 
approximately 15% of patients (Lu 2018). 
Individual risk of radiation-induced pneumonitis depends on the volume of lung treated and the 
radiation dose administered, as well as patient characteristics and other treatment modalities used 
(immunotherapy itself has around 10% pneumonitis risk on its own (Mohamad 2018). The risk 
of clinical pneumonitis requiring medical intervention has been reported to be 9% to 28% after 
lung SBRT (Kang 2015, Palma 2013, Yamashita 2014, Timmerman 2018). Many more patients 
show radiological changes, which can often disturb response evaluation, as well as show milder 
changer which itself can limit retreatments for metastatic disease in the same lung (Larici 2011, 
Kang 2015). Significant (≥ grade 3) rates of pneumonitis have been reported varying from > 10% 
to 21% (Timmerman 2006, Baumann 2009, Stephans 2018). Chemotherapy or/and 
immunotherapy carry their own pneumonitis risk and cumulative pneumonitis risk together with 
SBRT is observed and feared (Zhao 2016, Mohamad 2018, Palma 2013). 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 17 of 71 
 
 
With improved systemic treatment, lung cancer patients are also living long enough to manifest 
late pulmonary toxicity after RT (Larici 2011). Moreover, in patients with recurrent disease, re- 
challenging RT also becomes technically possible. Based on nonclinical data, fibrosis obtained 
following the first SBRT treatment can significantly limit future treatment options. Due to their 
close relation to major airways, esophagus and major vessels, central tumors have a higher 
complication risk from radiotherapy, and are in general treated with 5 or more fractions of SBRT 
(Lo 2009) allowing normal tissue in the field more time to repair (Timmerman 2006). 
In this trial, we target larger and/or central tumors associated with a higher pneumonitis and local 
failure risk, as well as a more fragile patient population. A sequential SBRT regimen of 5 
fractions or 3 fractions for larger peripheral lesions delivering dose up till biologically equivalent 
(total) dose (BED) of 100Gy aligns with the standard dose for larger and/or central lesions 
(Bejzak 2015, Timmerman JAMA 2010). The practice is shifting toward 5 fractions specifically 
for central localizations; however, for larger peripheral lesions, a 3-fraction regimen is still 
accepted. 
The RTOG 0813 trial identified SBRT dosing of 11.5 or 12 Gy x 5 fractions as associated with 
acceptable toxicity and with approximate 2-year rates for local control, overall survival, and 
progression-free survival of approximately 90%, 70%, and 55%, respectively (Bezjak 2019). 
Other studies (Stone 2015, Mohamad 2018) reported control rates around 70% and PFS 50-60% 
at 2 years. 
Radiation-induced lung injury is a slowly developing process, mostly manifesting as radiological 
changes only and transient symptoms around 4-6 months (mean 135 days) after treatment (Jain 
2018, Ferrero 2015). Clinically scored and symptomatic pneumonitis is seen in approximately 
10% of patients 6 months after SBRT (Kang 2015, Yamashita 2014, Mohamad 2018). Stone et al 
(2015) referred to DLCO decline as the most objective measure of lung toxicity, referring to an 
observed decline (grade 1 or more) in 20-30% of patients. While a small decline is not seen as 
clinically significant, it is predictive for more severe accumulative toxicity risk in cases of pre- 
existing lung disease or in those with subsequent need for re-treatment in the thoracic area. 
Radiological changes in lung parenchyma are observed in over 40% of SBRT patients (Kimura 
2006, Timmerman 2018). 
Approximately a 25% of patients experience declines in DLCO, reported after a 5-fraction 
regimen SBRT (Stone 2015). Slow decline in lung function and radiological changes are 
described after SABR/SBRT leaving a small portion of patients (mean 10%) with persistent 
significant decline at one year, which can be difficult to distinguish from recurrence (Huang 
2012). Both lung function testing and radiographical changes are directly related clinical scoring 
at 3 months (Tadasuke 2020), explaining a gradual change from radiological to functional and 
finally clinical symptomatic SBRT complication related to dose and volume treated. 
Both radiological and clinical data are needed to create future guidelines around lung SBRT 
(Mohamad 2018, Tadasuke 2020, Palma 2013). Complementary drugs such as GC4711 may add 
important value by increasing efficacy and reducing pneumonitis risk. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 18 of 71 
 
 
2.2 
Investigational Medicinal Product 
GC4711 is a novel, water soluble, low molecular weight, manganese-containing macrocyclic 
ligand complex whose catalytic activity for the dismutation of superoxide to hydrogen peroxide 
mimics that of naturally occurring superoxide dismutase (SOD) enzymes. GC4711 is a member 
of a new pharmacologic class of drugs termed selective dismutase mimetics and is being 
developed for administration as an intravenous (IV) infusion. The action of GC4711 to convert 
superoxide to hydrogen peroxide protecting normal lung tissue and potentiating antitumor 
response to SBRT. 
SOD enzymes are expressed in the cytoplasm (SOD1 Cu/Zn-based), mitochondria (SOD2, Mn- 
based), and extracellular spaces (SOD3, Cu/Zn- (O2•-) based) of mammalian cells (Fridovich 
1997). These enzymes eliminate superoxide (O2•-) by converting it to hydrogen peroxide which 
is then further detoxified by peroxidase enzymes to oxygen and water (Fukai 2011, Miller 2012). 
In certain inflammatory disease states and during RT and chemotherapy for cancer, native SOD 
enzyme activity can be overwhelmed due to excessive superoxide production resulting in normal 
tissue damage (Mapuskar 2019). Thus, the removal of excess superoxide with supraphysiological 
levels of SOD activity can protect normal tissues from therapeutic radiation damage as has been 
demonstrated by multiple lines of evidence (Greenberger 2007). Likewise, selective dismutase 
mimetics, specifically GC4711 analogues, have been shown to reduce normal oral mucosa 
damage due to radiation (Murphy 2008, Anderson 2019). 
Hydrogen peroxide is more toxic to tumor cells than to normal cells. This cancer cell sensitivity 
may reflect lower expression levels of catalase, glutathione peroxidase and other enzymes that 
degrade hydrogen peroxide in the cancer cell (Oberley 1997), a translocation of catalase (Bohm 
2015), or susceptibility of cancer metabolism. In irradiated tissue, radiation directly and 
indirectly generates additional superoxide which is then converted by SOD enzyme or dismutase 
mimetic to additional hydrogen peroxide. The amount of superoxide generated is related to RT 
fraction dose size, and thus the amount of hydrogen peroxide produced by the dismutase mimetic 
is also proportional to fraction dose size. As hydrogen peroxide increases with fraction dose size, 
it can reach levels that have significant anti-tumor effects (Greenberger 2007, Sishc 2018, Sishc 
2019). For example, the overexpression of manganese SOD (MnSOD, or SOD2) by plasmid 
liposomes in multiple mouse organs was shown to protect normal cells from radiation damage 
while increasing the radio-sensitivity of tumor cells, indicating that normal cells were protected 
from superoxide damage while tumor cells were susceptible to hydrogen peroxide (Greenberger 
2007). 
2.2.1 
GC4711 Nonclinical Data 
In nonclinical models, the addition of selective dismutase mimetics to SBRT regimens with or 
without concomitant systemic therapy enhanced antitumor activity while protecting normal 
tissues from radiation (Sishc 2019). The nonclinical development program for GC4711 is 
supported by previous findings in experimental NSCLC mouse xenograft models with GC4419, 
an analogue of GC4711 that is in clinical development to reduce the incidence and severity of 
oral mucositis due to radiation therapy for head and neck malignancies (Anderson 2019). 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 19 of 71 
 
 
Additional studies provided support for the hypotheses that dismutase mimetics (1) act as 
radiosensitizers in a hydrogen peroxide-dependent manner, and (2) act as a radioprotector 
reducing damage caused to normal lung tissue (Sishc 2018). 
In a series of nonclinical studies, GC4711 was evaluated for its ability to potentiate the antitumor 
effects of SBRT in experimental mouse xenograft models of lung and pancreatic cancers. In the 
human H1299 NSCLC model, GC4711 alone, administered once daily at 24 mg/kg for 
5 consecutive days, significantly delayed H1299 tumor growth in the xenografted mice 
compared with vehicle control animals (Figure 1). The administration of SBRT alone on Day 1 
at 18 Gy had an even greater effect on tumor growth. The combination treatment of 24 mg/kg 
GC4711 administered on Days 1 to 5 and 18 Gy SBRT on Day 1 demonstrated an additive effect 
on tumor growth, resulting in smaller average tumor volumes compared with GC4711 or SBRT 
alone. 
Figure 1 GC4711 Potentiated the Antitumor Effects of SBRT in a Human 
NSCLC Model 
 
NSCLC = non-small cell lung cancer; SBRT = stereotactic body radiotherapy. 
H1299 cells (ATCC® CRL-2553™) were implanted by subcutaneous (SC) injection into the flank of 6-week old 
female nu/nu mice. When the average tumor size per group reached 100 mm3, treatments were initiated. A 
single SBRT dose (18 Gy) was administered once on Day 1. Control and GC4711 groups (n = 9-12 animals per 
group) received the vehicle (10 mM sodium bicarbonate in saline) or 24 mg/kg GC4711 in vehicle by 
intraperitoneal (IP) injections approximately 30 minutes before the 18 Gy SBRT dose and on Days 2 through 5. 
Tumor dimensions were measured 2 times per week by caliper and tumor volumes calculated. Tumor volumes 
expressed as the group mean +/- standard error of the mean. 
 
The inclusion of radiation dose holidays in the H1299 model did not decrease the inhibitory 
effect of the GC4711-SBRT combination. In addition, in focal irradiation models in non-tumor 
bearing mice the GC4711 analogue, GC4419, potently reduced normal lung damage at single RT 
doses up to 60 Gy (Sishc 2018). 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 20 of 71 
 
 
SBRT greatly increases cellular superoxide concentrations, which these selective dismutase 
mimetics exploit to generate high levels of hydrogen peroxide, creating a highly toxic 
environment for tumor cells. The hypothesis that the antitumor response was driven by the 
overwhelming and persistent production of hydrogen peroxide is supported by the observation 
that the dismutase mimetic-enhanced radiation response of tumors derived from H1299CAT 
cells (doxycycline-inducible catalase overexpressing) and treated accordingly with doxycycline, 
was completely abrogated (Sishc 2018). The conversion of superoxide to hydrogen peroxide 
catalyzed by dismutase mimetics renders tumor cells more sensitive to the effects of SBRT, 
positively impacting tumor cure rates in nonclinical in vivo models. 
That GC4711 administration will also protect normal tissues from radiation-induced damage is 
supported by studies with the GC4711 analogue, GC4419 (Sishc 2018). In these studies, GC4419 
acted as both a protector and mitigator of radiation-induced damage. A single pretreatment with 
GC4419 significantly reduced the fibrotic density of focally irradiated murine lung tissue (54 Gy 
and 60 Gy, single dose). Furthermore, daily post-irradiation dosing of GC4419 also further 
reduced lung fibrosis dependent upon the total duration of daily delivery. 
Four GLP 14-day repeat-dose studies with 14-day non-treatment recovery periods were 
conducted in SD rats and beagle dogs using either 15- or 60-minute GC4711 IV infusions in each 
species. In GLP toxicology studies conducted in rats, GC4711 had no test item-related adverse 
effects on CNS or respiratory parameters when administered as repeat-dose 15-minute IV 
infusions; furthermore, in single- and repeat-dosing safety pharmacology studies performed with 
GC4711 in dogs, no adverse CV effects occurred following 15-minute IV infusions, the intended 
route of administration in human subjects. 
Key safety findings in the GLP toxicity studies were as follows: 
• GC4711 was overall well tolerated in SD rats and beagle dogs in all repeat-dose studies. 
• Mortality was observed in 2 rats in the 15-minute infusion study at the high dose of 
16 mg/kg/day and was of unknown relationship to GC4711. 
• Adverse effects included weight loss, which was observed in rat 15- and 60-minute 
infusion studies at the high dose of 16 mg/kg/day (15-minute infusion), and the middle 
and high doses of 18 mg/kg/day and 24 mg/kg/day (60-minute infusion), respectively. 
The rat adverse effects were reversible during the 14-day recovery period. 
• The NOAEL was considered to be 8 mg/kg/day for rats and 9 mg/kg/day for dogs in the 
15-minute GC4711 infusion studies. The NOAEL was considered to be 12 mg/kg/day for 
rats and 12.5 mg/kg/day for dogs in the 1-hour GC4711 infusion studies. 
• There were no indications of clastogenicity or genotoxicity associated with 
administration of GC4711. 
For additional information, please refer to the GC4711 Investigator’s Brochure. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 21 of 71 
 
 
2.2.2 
GC4711 Clinical Data 
The clinical development of GC4711 comprises one completed and two ongoing clinical studies. 
Initially, the safety and plasma exposure of healthy volunteers to GC4711 was compared to that 
of the analogue, GC4419, which is in development for reduction of RT-induced oral mucositis 
(Study GTI-4711-001). Based on their structural similarities, it was hypothesized that, at 
equimolar doses administered by the same route and schedule, the safety and plasma exposure of 
GC4711 and GC4419 in human subjects would be substantially similar. This was demonstrated 
in GTI-4711-001, facilitating further work to identify GC4711 doses of interest for clinical study 
in light of prior experience with GC4419. Additional information regarding the safety and 
pharmacokinetic results of this completed study are available in the Investigator’s Brochure. 
In addition, safety data with GC4711 have been obtained at a dose of 30 mg by 60-minute IV 
infusion in an ongoing study (Study GTO-003) in which the bioavailability of various candidate 
oral formulations of GC4711 is being assessed to identify a suitable formulation for future 
clinical development. 
The principal study supporting the proposed dosing of GC4711 in the current Phase 1/2 study 
was a Phase 1 Study (Study GTI-4711-002). In this study, serial cohorts of healthy volunteers 
received IV GC4711 or placebo by 15-minute IV infusion period at a single dose up to 120 mg 
of GC4711, then by multiple infusions once daily for 14 days at 90 mg/day. 
In Study GTI-4711-002, a total of 10 subjects were enrolled in each cohort and were randomized 
at a 6:4 ratio to receive GC4711 or placebo treatment. All cohorts included a sentinel cohort 
consisting of 2 subjects (1 GC4711, 1 placebo) who were observed for at least 24 hours with 
safety data reviewed by the treating investigator before dosing the rest of the subjects in the 
cohort. In the SAD cohorts (Cohorts 1-6), GC4711 or placebo was administrated as a single dose 
on Day 1 at 30, 60, 75, 90, 105, or 120 mg. In the multiple dose cohort (Cohort 7), GC4711 or 
placebo was administrated once daily for 14 days at 90 mg/day. 
In Study GTI-4711-002, the PK profile of GC4711 following 15-minute IV infusion at doses 
from 30 mg to 120 mg as a single dose and 90 mg/day for 14 days in Study GTI-4711-002 is 
characterized by: 
• Quantifiable plasma concentrations up to 6 to 12 hours across all dose cohorts. 
• Greater than dose proportional behavior for the Cmax and AUC of GC4711 across single 
dose administration cohorts. For GC4711 this behavior may be attributed to the fact that 
the first dose (30 mg) was not measurable for a long period of time, resulting in a much 
lower AUC. 
• The t1/2 for GC4711 was approximately 2 hours. 
• Low levels of exposure to the GC4711 metabolites GC4764 and GC4765, with 
metabolite to parent ratios of < 6% and 1.2%, respectively across all dose cohorts. Based 
on the combination of low prevalence and biological activity in nonclinical studies, these 
metabolites do not appear to be of clinical significance in human patients. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 22 of 71 
 
 
• No marked accumulation of GC4711 was observed by Day 8 following daily 
administration of 90 mg/day. 
The safety of GC4711 has been established following administration by IV infusion in healthy 
volunteers. Overall, the safety profile of GC4711 was comparable following single 15-minute IV 
infusion doses up to 120 mg and multiple 15-minute IV infusion doses of 90 mg/day for 14 days. 
Consistent with the mechanism of action of GC4711 (specifically, potentiation of nitric oxide 
(Kasten 1995)), transient orthostatic symptoms (e.g., headache, dizziness, light-headedness), 
hypotension, facial tingling or paresthesia were expected and consistently observed. Reports of 
paresthesia appeared to be dose-related; however, it was mild to moderate in intensity and was 
not treatment-limiting. All TEAEs reported have been Grade 1 or Grade 2 in intensity. None of 
the TEAEs were graded serious and there were no deaths. None of the clinical laboratory 
evaluations resulted in any clinically significant abnormalities. Please see the Investigator’s 
Brochure for further details. 
Assessment of ECG data from the single ascending dose cohort of the ongoing Phase 1 study 
(Study GTI-4711-002), demonstrated that there were no clear dose-related trends, nor changes in 
ECG measures nor interpretation from normal to abnormal, which were clinically significant. 
Overall, there were 3 subjects (1 [16.7%] at 30 mg and 2 [33.3%] at 120 mg) who reported ECG 
changes that were all judged not clinically significant. This addressed shifts in QT interval at 
2 hours post end of infusion relatively to baseline (-5.3 msec for the subject in the 30 mg group 
and +5.0 and +16.7 msec for the subjects 120 mg group, respectively) and QTcF interval 
(-5.3 msec for the in the subject in the 30 mg group and +9.0 and +7.7 msec for the subjects 
120 mg group, respectively). Although, rated as clinically non-significant, ECG and QT intervals 
are to be closely followed when patients are first exposed to GC4711. 
Overall, the safety profile of GC4711 from healthy volunteer populations is acceptable to further 
investigate safety testing in NSCLC patients. 
 
2.3 
GC4711 Benefit/Risk Assessment 
The safety of GC4711 has been established in healthy subjects following administration via 15- 
minute and 60-minute IV infusions. There were no unexpected safety findings, and the overall 
safety profile of GC4711 was comparable following single 15-minute IV infusion doses up to 
120 mg and multiple 15-minute IV infusion doses of 90 mg/day for 14 days. Further, a crossover 
study in healthy human subjects demonstrated similar safety and plasma exposure to the 
MnPAM dismutase mimetic analogues GC4711 and GC4419 administered via IV infusion at 
approximately equimolar doses. A 100 mg dose of GC4711 is approximately equimolar to the 90 
mg dose of GC4419 used in the pilot SBRT combination trial in patients with pancreatic cancer 
and in the IMRT combination oral mucositis clinical trials in head and neck cancer. 
Therefore, based on non-clinical pharmacology studies and previously collected clinical data, 
GC4711 is an appropriate experimental drug candidate in combination with SBRT as a safe and 
effective alternative in lung cancer management. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 23 of 71 
 
 
3 OBJECTIVES AND ENDPOINTS 
 
OBJECTIVES 
ENDPOINTS 
Phase 1 
Primary 
- 
To assess the safety of GC4711 
administered intravenously (IV) in 
combination with 5 fractions of 
stereotactic body radiation therapy 
(SBRT) in subjects with Non-small Cell 
Lung Cancer (NSCLC) 
- 
Number of dose-limiting toxicities 
(DLTs) occurring during treatment with 
SBRT and GC4711/placebo or within 30 
days post-SBRT 
Secondary 
- 
To evaluate the efficacy, and acute and 
late toxicities of GC4711 + 5 fractions of 
SBRT 
Measurement of the following parameters 
over 24 months after SBRT 
- 
Efficacy: 
o Progression Free Survival (PFS) 
o Overall Survival (OS) 
o Local and regional control 
o Distant Metastases (DM) rate 
Measurement of the following parameters 
over 12 months after SBRT: 
- 
Toxicity: 
o Changes in pulmonary function 
testing: Pulse oximetry (SpO2), forced 
vital capacity [FVC], first expiratory 
volume in the first second [FEV1], 
DLCO, clinical and radiological 
pneumonitis scorings. 
o Frequency, duration and severity of 
AEs and SAEs 
o ECG and Pharmacokinetics 
monitoring of GC4711 
- 
To evaluate the long-term toxicity of 
GC4711 + 5 fractions of SBRT 
- 
Late radiotherapy (RT) Toxicities 
(including clinical and radiographic 
pneumonitis, esophagitis, pulmonary 
fibrosis, rib fractures) up to 12 months 
following the completion of SBRT 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 24 of 71 
 
 
 
OBJECTIVES 
ENDPOINTS 
Phase 2 
Primary 
- 
To determine the percentage of patients 
with complete or partial in-field tumor 
response through 6 months following 
SBRT 
- 
Percent of patients with a best RECIST 
response of CR or PR amongst all 
responses through Month 6 
Secondary 
- 
To determine the degree of in-field tumor 
response at 6, 12, 18 and 24 months 
following completion of SBRT 
- 
To compare progression-free survival, 
overall survival, local tumor control, and 
distant metastasis rates over a 2-year 
follow up period for SBRT plus GC4711 
or placebo 
- 
To assess durability of in-field complete 
or partial responses 
- 
To determine acute lung toxicity after 
SBRT + GC4711 compared to SBRT + 
placebo for early-stage NSCLC 
- 
To evaluate the rate of acute and late 
radiation toxicities for SBRT + GC4711 
compared to SBRT + placebo 
- 
To assess the relationship between 
clinical, functional and radiographical 
lung function changes observed after 
SBRT 
- 
- 
Percent reduction of in-field tumor at 
Months 6, 12, 18 and 24 
- 
Number of participants with CR+PR 
- 
Number of participants experiencing 
grade 1 or higher in diffusion capacity of 
lung for carbon monoxide (DLCO), 
measured by RTOG scale, at 6-months 
after the completion of SBRT 
- 
Measurement of the following parameters 
over 12 months after SBRT 
- Changes in pulmonary function 
testing (pulse oximetry [SpO2], 
forced vital capacity [FVC], first 
expiratory volume in the first second 
[FEV1], DLCO), clinical and 
radiological pneumonitis scoring 
- Reporting of observed adverse events 
in patients 
- Late Radiation Toxicities (including 
clinical and radiographic 
pneumonitis, esophagitis, pulmonary 
fibrosis, rib fractures, plexopathy, 
cardiac and vascular events) up to 
12 months following the completion 
of SBRT 
- 
Measurement of the following parameters 
over 24 months after SBRT 
- Progression Free Survival (PFS) 
- Overall Survival (OS) 
- Local and regional control 
- Distant Metastases (DM) rate 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 25 of 71 
 
 
 
OBJECTIVES 
ENDPOINTS 
- 
Exploratory (Phase 1 and 2) 
- 
To evaluate lung injury risk over time 
- 
To evaluate the relation between clinical, 
functional and radiographical lung 
function changes and patient/disease and 
dosimetry characteristics 
- 
To evaluate the pharmacokinetics of 
GC4711 in the study population 
- 
To collect initial information about acute 
effects of GC4711 on electrocardiogram 
parameters 
- 
Lung functional decline over time 
- 
Risk factor analysis for decline in lung 
function, imaging and clinical scoring of 
pneumonitis, including dosimetry, disease 
and patient characteristics (smoking, 
medical history) 
- 
ECG and Pharmacokinetics monitoring of 
GC4711 
4 STUDY DESIGN 
4.1 
Overall Design 
GTI-4711-101 is a Phase I/II study of the safety of GC4711, and its potential to reduce radiation- 
related pulmonary injury, in combination with SBRT for clinical Stage I/II lymph node negative 
(T1 to T3N0M0) and/or central localized NSCLC. 
After an open-label, Phase 1, safety run-in cohort of approximately 5 subjects has been completed, 
a randomized, placebo-controlled Phase 2 portion will be conducted. 
Subjects must be referred for SBRT with peripheral lesions (>1-7 cm) or central localized (within 
an all direction, 2 cm- zone around the proximal bronchial tree, including ultra-central lesions, 
abutting the proximal bronchial tree or trachea) and node negative, non-metastatic NSCLC and 
have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-3 to be 
considered for enrollment (Buccheri 1996). Subjects with small peripheral lesions (≤1cm) are 
excluded, as we aim to improve outcome in larger, central NSCLC carrying a higher risk of 
pneumonitis and other RT related toxicities (including esophagitis, rib fractures, fistulae, stenosis, 
plexopathy, pericarditis, vascular events, etc. see Section 7.4), as well as local control failure. 
Feasibility of SBRT is judged by the treating physician. SBRT is planned on the tumor location 
for a dose of 10-12 Gy per 5 fractions, delivered on 5 sequential days or a dose of 18-20 Gy per 3 
fractions (minimum of 18 and maximum of 96 hours between fractions for either regimen). All 
fractions should be given within 10 calendar days (+5 days in the case of a holiday or technical 
issue). 
Phase 1: 5 subjects will each receive 100 mg of GC4711 by 15-minute IV infusion, before each 
SBRT fraction, beginning the day of the first fraction and ending the last day of SBRT (5 doses in 
total). SBRT is administered within 180 minutes (3 hours) of the end of the GC4711 infusion. All 
5 SBRT doses should be given within 10 calendar days. All 5 subjects will be monitored for dose 
limiting toxicity (DLT) for 30 days post SBRT plus GC4711. DLT is defined in Section 7.5. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 26 of 71 
 
 
Safety will be judged unacceptable if 2 or more (i.e., no more than one) of the 5 subjects develop 
a DLT. Safety will be reviewed by a Safety Review Committee (SRC) consisting of the Medical 
Monitor, the Principal Investigator from each Phase 1 site, and additional designees by the Sponsor 
or the site Principal Investigators. 
Phase 2: After the SRC has confirmed acceptable safety in the Phase 1, a Phase 2, randomized, 
placebo-controlled study phase will be initiated, wherein approximately 66 subjects referred for 
SBRT with early stage large and/or central localized NSCLC will be randomized in a 1:1 ratio to 
receive either GC4711 100 mg or placebo given IV over 15 minutes on each day that SBRT is 
given, beginning the day of the first fraction of SBRT and ending the last day of SBRT,. SBRT is 
administered within 180 minutes (3 hours) of the end of the GC4711 infusion. A minimum of 18 
hours and a maximum of 96 hours are permitted between factions. All fractions should be given 
within 10 calendar days (+3 days in the case of a holiday or technical issue). 
All subjects will be evaluated for changes in the in-field tumor for 24 months following completion 
of SBRT. The primary endpoint will evaluate the percentage of patients with complete or partial 
in-field tumor response through 6 months following SBRT. In addition, as a secondary endpoint, 
the percent of subjects with overall responses (PR + CR) per RECIST 1.1 will be evaluated. 
All subjects will be evaluated by changes in the diffusion capacity of lung for carbon monoxide 
(DLCO), as assessed by the RTOG grading scale monitored at 6 months and 12 months. The 
secondary endpoints will evaluate all lung function parameters. Pneumonitis will also be assessed 
both clinically and radiographically (CTCAE 5.0). 
All subjects will be followed for 30 days post SBRT completion for treatment related adverse 
events, 90 days post SBRT completion for acute radiation toxicity and for 12 months post SBRT 
completion for late radiation toxicity, and will be followed for 24 months post SBRT completion 
for local and regional disease control (LC), Progression Free Survival (PFS), Overall Survival (OS) 
and Distant Metastases (DM) rate. 
Detailed information on the Radiation Therapy Quality Assurance (RTQA) (Phase 1 only) and 
dose-volume exposure, concomitant medications and existing obstructive lung disease will be 
collected for pneumonitis-risk analyses. 
Pharmacokinetic (PK) sampling and cardiac monitoring will be performed on each subject with 
two separate doses of GC4711 (or placebo) collecting blood samples pre-infusion post-infusion 
and 24 hours post-infusion (Phase 1 only) for each. 
In Phase 2, the Sponsor will perform routine reviews of the safety data at an interval no less than 
quarterly and after the 20th randomized subject reaches the 30-day follow up timepoint, 
whichever occurs first. See Section 8.6 for details. 
4.2 
Study Duration for Participants 
The study duration for participants is expected to be approximately 25 months. This includes a 
21-day screening period, a treatment period of approximately 5-10 days, and long-term follow- 
up for 24 months. All subjects are evaluated 30 days after SBRT and 6, 12, 18 and 24 months 
post-SBRT. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 27 of 71 
 
 
If a participant experiences progressive disease prior to 24 months post-SBRT completion, they 
will continue for survival follow-up until end of study (24 months following the last 
administration of SBRT). No additional tumor assessments will be required after progression; 
however, adverse events for long term radiation toxicities will continue through 12 months post 
SBRT completion and survival follow up will continue through 24 months post SBRT 
completion. 
4.3 
Number of Participants 
Approximately 71 participants will be enrolled in the study. This includes 5 in the Phase 1 
portion and approximately 66 in the Phase 2 portion 
4.4 
Replacement of Participants 
In Phase 1, if a subject is withdrawn from the study prior to completing GC4711/Radiotherapy 
and 30 days of follow-up without experiencing a DLT prior to withdrawal, an additional subject 
may be added. 
In Phase 2, patients who are randomized but do not receive study drug may be replaced. 
4.5 
Number of Sites 
Phase 1: Up to 4 sites in the US will participate in the Phase 1 portion. 
Phase 2: Up to 20 sites in the US will participate in the Phase 2 portion. 
4.6 
End of Study Definition 
End of Study (Individual Participant): A participant is considered to have ended participation 
in the study if he/she has completed all phases of the study including the month 24 follow-up or 
who as withdrawn consent from all study participation or who has died. 
Primary Completion: The primary completion date is defined as the date when the last 
participant is assessed or receives an intervention for the final collection of data for the primary 
endpoint(s) for the purposes of conducting the primary analysis. For Phase 1, this is defined as 
30 days post SBRT. For the Phase 2, this is defined as 6 months post SBRT. 
End of Study (End of trial): The date the final participant was examined or received an 
intervention/assessment for purposes of final collection of data for the primary, secondary or 
exploratory outcome measures. 
4.7 
Rationale for Study Design 
In non-clinical development, GC4711 has shown the potential of increasing efficacy of high dose 
RT as well as limit associated inflammatory and fibrotic normal tissue reactions. As SBRT is a 
commonly used high dose RT treatment for early NSCLC, in this trial, we combine 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 28 of 71 
 
 
GC4711/placebo with this national standard SBRT indication. Though SBRT has been shown to 
be effective in the treatment of small peripheral NSCLC (Timmerman 2010), its use for larger 
and/or central lesions has been associated with an increased risk of toxicity and less favorable 
local control (Stanic 2014, Bezjak 2015). By combining GC4711 with the 5-fraction regimen 
(Timmerman 2006, Lo 2010, Ettinger 2020), this study will assess both tolerability of the 
regimen and disease control. In addition to the routine efficacy parameters of local and regional 
control, control of distant metastatic rate, progression free survival (PFS) and overall survival 
(OS), we will also examine the effects of SBRT and GC4711 on response rate by the RECIST 
1.1 criteria and degree of in-field tumor response. 
 
Lung damage is the most common reported adverse effect and close monitoring of pneumonitis 
in this trial can be compared to extensive historical data (Timmerman 2006, 2010 and 2018). 
Radiation induced injury is a slow developing process, showing most radiological changes and 
symptoms around 3-6 months after treatment (Takeda 2013, Videtic 2013, Jain 2018, Ferrero 
2015). Approximately 25% of patients treated with a 5-fraction regimen of SBRT encounter lung 
function decline (Stone 2015), of which a small portion (mean 10%) remain with a significant 
decline, which can be difficult to distinguish from recurrence (Huang 2012). Radiological 
changes have been described in larger number of subjects but are not always translated in clinical 
symptoms. Safety of GC4711 is the primary endpoint of the phase 1 portion and acute and late 
RT toxicities, as well as disease outcome are monitored as secondary endpoints in phase 2. 
 
4.8 
Rationale for GC4711 Starting Dose 
The proposed dosing regimen for this study will consist of 100 mg IV of GC4711 administered 
over 15 minutes prior to each SBRT fraction. Patients will be required to receive a total of 3 x 
18-20 Gy or 5 x 10-12 Gyfor a total 50 to 60 Gy. Following the healthy human volunteer study 
(GTI-4711-002), IV administration of GC4711 was found to be well-tolerated following a single 
administration at dose levels up to 120 mg and following repeated dosing of 90 mg/day for 14 
days or a total weekly dose of 630 mg. Therefore, GC4711 at a dose of 100 mg x 3 or 5 doses 
(aligning with SBRT regimen) is expected to be tolerated by this patient population. 
This dose level is also supported by nonclinical safety studies. Based on the STD10 (the dose in 
non-clinical studies that was severely toxic to 10% of the rodents) and the highest non-severely 
toxic dose (HNSTD) calculations using the GLP 14-day rat (Study 1324-4711-0520) and dog 
(Study 1325-4711-0520) toxicology studies, a 90 to 96 mg/patient starting dose of GC4711 are 
supported. 
Further, GTI-4711-001 demonstrated substantially similar safety and pharmacokinetics of 
GC4711 and GC4419. Acceptable safety of a 90 mg dose of GC4419 (approximately equimolar 
to 100 mg of GC4711) has been observed with GC4419 administered to head and neck cancer 
patients, M-F for up to 7 weeks, in combination with intensity-modulated radiotherapy (IMRT) 
and concurrent cisplatin (Anderson 2019). Adverse effects associated with either drug have been 
transient in clinical trials or have not appeared to be worse with repeat dosing (Anderson 2019). 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 29 of 71 
 
 
5 SELECTION AND WITHDRAWAL OF SUBJECTS 
Before any study-specific activities/procedures, the appropriate written informed consent must 
be obtained (see Appendix 1). 
5.1 
Inclusion Criteria 
Participants are eligible to be included in the study only if all the following criteria apply: 
1. Male or female subjects at least 18 years of age. 
2. Ability to understand and the willingness to sign a written informed consent. 
3. Histological or biopsy proven NSCLC. For peripheral lesions, cytology and/or clear 
imaging-guided suspicion is accepted if histology cannot be obtained. 
4. ECOG performance status of 0-3. 
5. Lymph node negative (T1 to T3N0M0), centrally located (within 2cm in all 
directions around the proximal bronchial tree, including ultra-central tumors, 
abutting the bronchial tree or trachea) or large (>1-7cm) Non-Small Cell Lung 
Cancer (NSCLC) , judged acceptable for SBRT by the treating Investigator. Staged 
with FDG-PET/CT, brain CT or MRI with contrast and/or mediastinoscopy, 
measurable disease as defined by RECIST 1.1. (See Figure 2 below). 
6. Adequate end-organ function, based on routine clinical and laboratory workup: 
a. ANC >1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 8.0 g/dl 
b. Serum creatinine ≤ 2 mg/dL or calculated creatinine clearance ≥ 30 ml/min 
c. Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and 
ALT ≤ 2.5 x ULN 
d. International normalized ratio (INR) (or prothrombin time (PT)) and 
activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant 
is receiving anticoagulant therapy, if values are within the intended 
therapeutic range 
7. Males and females of must agree to use effective contraception starting prior to the 
first day of treatment and continuing after the last dose of GC4711/Placebo for 30 
days (females) and 90 days (males). 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 30 of 71 
 
 
 
 
Figure 2 
Anatomy of central and ultra-central lung tumors 
Timmerman and colleagues defined central lung tumors as those located within 2 cm of the 
proximal bronchial tree (Timmerman 2006). Here defined ultra-central lung tumors as those 
abutting the proximal bronchial tree or trachea (Lo 2010, Chaudhuri 2015, Chang 2018). 
 
5.2 
Exclusion Criteria 
Participants are excluded from the study if any of the following criteria apply: 
1. Subjects with confirmed nodal and/or distant disease (including brain), according to 
standard workup by local investigator. 
2. Subjects with peripheral lesions of 1cm or smaller 
3. Prior treatment with immunotherapy within 3 months prior to Day 1 dosing. 
4. Prior intra-thoracic radiotherapy or surgery with substantial overlap to planned in 
former radiation fields as determined by the treating radiation oncologist. 
5. Subjects not recovered/controlled from prior treatment-related (chemotherapy or 
targeted therapy) toxicities judged by treating physician. 
6. Uncontrolled malignancy other than lung cancer that requires active treatment or is 
deemed by the treating physicians to be likely to affect the subject's survival duration. 
7. History of allergic reactions attributed to compounds of similar chemical or biologic 
composition to GC4711. 
8. Uncontrolled intercurrent illness including, but not limited to, active infection, 
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or 
psychiatric illness/social situations that, in the opinion of the investigator, would limit 
compliance with study requirements. 
9. Participation in other clinical trials actively testing new anti-cancer treatments unless 
previous written approval provided by the Sponsor. 
10. Requirement for concurrent treatment with nitrates or other drugs that may, in the 
judgment of the treating investigator, create a risk for a precipitous decrease in blood 
pressure. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 31 of 71 
 
 
11. Female subjects who are pregnant or breastfeeding. 
12. Any other conditions that, in the Investigator’s opinion, might indicate the subject to be 
unsuitable for the study. 
 
5.3 
Screen Failures 
A subject is considered as a screen failure if the subject signs the ICF but withdraws consent or is 
deemed ineligible prior to registration/randomization. The reason why the subject was precluded 
from the clinical study will be recorded in the medical record and eCRF. Individuals who do not 
meet the criteria for participation in this study (screen failure) may be rescreened. 
 
5.4 
Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
Subject Study Withdrawal: A subject has the right to withdraw from the study at any time for 
any reason. Subjects who withdrawal consent from study treatment and/or study assessments 
early should be encouraged to continue with survival and late toxicity follow-up, if feasible. 
 
Subject Study Discontinuation: The Investigator or Sponsor may also, at his/her discretion, 
discontinue a subject from participating in this study at any time. 
 
Study Intervention Discontinuation: A subject may discontinue study treatment but remain in 
the study for follow-up for any of following reasons: 
• 
A protocol violation (reason must be specified, for example: lack of compliance, 
use of a prohibited concomitant medication, failure to meet inclusion/exclusion 
criteria after study entry, etc.) 
• 
The subject was “lost to follow-up” 
• 
Unacceptable adverse event necessitating treatment cessation 
• 
More than three infusion modifications of GC4711/placebo 
• 
Subject requests to withdrawal from the study treatment 
• 
Subject becomes pregnant 
• 
Other reasons (reason must be specified, for example: the subject moved, 
investigator decision, Sponsor decision to terminate trial, etc.) 
If a subject discontinues from the study treatment early (did not complete SBRT regimen and/or 
receive all protocol required infusions of study drug), they will continue to be followed for 
progression, toxicities and survival as outlined in the SOA. 
 
The primary reason and date for ceasing treatment, discontinuation and/or subject withdrawal 
will be clearly documented in the subject’s medical record and recorded on the appropriate CRF 
page. 
Discontinuation of specific study sites or of the study are handled as part of 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 32 of 71 
 
 
Appendix 1. 
6 INVESTIGATIONAL PRODUCT AND TREATMENT OF SUBJECTS 
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the 
study protocol. 
Refer to the GC4711 IB and Pharmacy Manual for more detailed information regarding the 
storage, preparation, destruction, and administration of each treatment. 
The site pharmacists will be unblinded to the treatment assignments. The Principal 
Investigator and remainder of the site staff will be blinded to treatment assignment. The 
Unblinded Pharmacist should take every precaution to prepare the study treatment in a blinded 
fashion and out of site from the Blinded site clinical staff. The Blinded Clinical Staff should be 
mindful of the steps in place to maintain the blind. 
6.1 
Investigational Product: GC4711/Placebo 
GC4711 Dosage Formulation and Preparation 
GC4711 IV drug product is formulated as a lyophilized solid in a vial and reconstituted shortly 
before administration with a provided 26 mM sodium bicarbonate aqueous buffer diluent. Sterile 
drug product and diluent will be provided by Galera Therapeutics Inc., and the drug product will 
be supplied as 120 mg in 3 mL clear glass vials and reconstituted by adding 1.10 mL of the 
provided diluent to yield 100 mg/mL reconstituted drug product. GC4711 (reconstituted 
solution) will be prepared by the unblinded pharmacist, diluted in normal saline (0.9% NaCl) to 
obtain a 100 mL dosing solution for IV infusion. 100 mL Normal saline (0.9% NaCl) for IV 
infusion, supplied by the site, will be used as placebo. 
GC4711 Dosage, Administration, and Schedule 
Phase 1: 
100 mg/day of GC4711 IV will be given over 15 minutes, starting from the first to the last 
SBRT treatment. GC4711 will be given before SBRT with a maximum of 180 minutes 
between end of infusion and the start of SBRT. 
 
Phase 2: 
- 
Arm A: 100 mg/day of GC4711 will be given via IV infusion over 15 minutes, prior to each 
SBRT dose, from the first to the last SBRT treatment. On days of SBRT, GC4711 will be 
administered with a maximum of 180 minutes between the end of infusion and the start of 
SBRT. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 33 of 71 
 
 
- 
Arm B: Placebo (normal saline) will be administered via IV infusion over 15 minutes to be 
completed with a maximum of 180 minutes prior to SBRT as for Arm A. 
A total of 100 mL of GC4711 or Placebo (normal saline) will be infused IV over a 15-minute 
period using a programmable pump, when feasible. Each infusion should be given before each of 
the SBRT treatments (Table 1 Schedule of Activities). In situations where SBRT is not given 
following study drug infusion, an additional dose of GC4711/placebo may be given prior to the 
rescheduled fraction. 
GC4711 Drug Packaging and Labeling 
GC4711 with diluent will be provided by Galera as single-use vials for daily doses to be 
administered IV concurrent with SBRT. The drug product is supplied as 120 mg in 3 mL clear 
glass vials along with 26 mM sodium bicarbonate buffer diluent which is packaged in a 3 mL clear glass 
vial. Each vial will be labeled with the appropriate language, including the required regulatory 
text. 
 
Normal saline will be provided and prepared by the site institutional pharmacy for subjects 
assigned to placebo in the Phase 2 portion of the study. 
Maintenance of the Blind 
All staff at the site should be designated as either blinded or unblinded. For Phase 2, the site 
pharmacists will be unblinded to the treatment assignments assigned within the Randomization 
and Trial Supply Management (RTSM) System. 
Unblinded pharmacy staff will be responsible for management and accountability of 
investigational product and preparation of study drug in a blinded fashion. The unblinded 
pharmacy staff will ensure the double-blind nature of this study and will not share the treatment 
assignment directly or indirectly (IP Accountability Logs, IV bag labels, etc.) with the blinded 
site staff. Sites should be able to provide documentation regarding how the blind is maintained 
at their sites. 
The site pharmacists will obtain treatment assignments for subjects via the Randomization and 
Trial Supply Management System (RTSM) through their unique username and password, which 
should not be shared. Blinded staff will not have access to the treatment assignments via the 
RTSM. Preparation of the assigned treatment group (GC4711 or placebo) can also be found in 
the Pharmacy Manual. 
Investigational Product Storage and Accountability 
GC4711 should be stored in the pharmacy at -15°C to -25°C. The sodium bicarbonate aqueous 
buffer diluent will also be stored in the pharmacy. The diluent must be stored under refrigerated 
conditions (2 to 8ºC) and must not be frozen. The storage temperature should be monitored and 
recorded daily as per site SOPs to ensure temperatures are maintained per above. Copies of 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 34 of 71 
 
 
temperature monitoring logs will be made available to the CRA upon request. The sponsor must 
be notified of any deviation from the specified storage conditions. 
Study drug must always be kept in a secure place with access limited to the unblinded pharmacy 
staff under the appropriate storage conditions. All unblind personnel involved in the dispensing 
of study drug should be aware of its location. Any deviations in accountability and/or storage 
should be reported to the site CRA immediately. 
Study Intervention Compliance 
Study drug will be administered under the supervision of study site personnel. The infusion 
volume and timing of each dose will be recorded. Accidental overdoses should be reported to the 
Sponsor/designee promptly. 
 
6.2 
Stereotactic Body Radiation Therapy (SBRT) 
SBRT Dosage, Administration, and Schedule 
Patients will be evaluated by the treating radiation oncologist at the local site. Based on location 
and size of the tumor, dose planning will be determined by clinical appropriateness that balances 
ablation of the lesion(s) while respecting normal tissue constraints including for ultra-central 
lesions the volume criterium of the contoured proximal bronchial tree less than 0.03cc =<52.5Gy 
(Bejzak 2019). 
Table 2 Organ Constrains for a 3-Fraction SBRT Regimen 
 
Serial Tissue 
Volume 
(cc) 
Volume 
Max 
(Gy) 
Max Point Dose 
(Gy)2 
Endpoint (≥Grade 3) 
Esophagus1 
<5 
27.9 
32.4 
Esophagitis 
Brachial Plexus 
<3 
22 
26 
Neuropathy 
Heart/Pericardium 
<15 
24 
30 
Pericarditis 
Great vessels 
<10 
39 
45 
Aneurysm 
Trachea and Large 
Bronchus1 
<5 
39 
43 
Impairment of 
pulmonary toilet 
Bronchus smaller 
airways 
<0.5 
25.8 
30 
Stenosis with 
atelectasis 
Rib 
<5 
40 
50 
Pain or fracture 
Lung (Right & Left) 
1500 for males; 950 for 
females3 
10.8 
Basic Lung Function 
Lung (Right & Left) 
V-11.4Gy<37% 
Pneumonitis 
Spinal cord 
<0.35 
15.9 
22.5 
Myelitis 
Abbreviations: 
1. Avoid circumferential irradiation 
2. “point” defined as 0.035cc or less 
3. or one-third of the “native” total organ volume (prior to any resection or volume reducing disease), whichever is greater: 
• 
Exceeding these dose tolerances by more than 2.5% constitutes a minor protocol violation. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 35 of 71 
 
 
• 
Exceeding these dose tolerances by more than 5% constitutes a major protocol violation. 
 
 
Table 3 
Organ Constraints for a 5-Fraction SBRT Regimen 
 
Serial Tissue 
Volume 
(cc) 
Volume 
Max 
(Gy) 
Max Point Dose 
(Gy)2 
Endpoint (≥Grade 3) 
Esophagus1 
<5 
32.5 
38 
Esophagitis 
Brachial Plexus 
<3 
27 
32.5 
Neuropathy 
Heart/Pericardium 
<15 
32 
38 
Pericarditis 
Great vessels 
<10 
47 
53 
Aneurysm 
Trachea and Large 
Bronchus1 
<5 
45 
50 
Impairment of 
pulmonary toilet 
Bronchus smaller 
airways 
<0.5 
32 
40 
Stenosis with 
atelectasis 
Rib 
<5 
45 
57 
Pain or fracture 
Lung (Right & Left) 
1500 for males; 950 for females3 
12.5 
Basic Lung Function 
Lung (Right & Left) 
V-13.5Gy<37% 
Pneumonitis 
Spinal cord 
<0.35 
22 
28 
Myelitis 
Abbreviations: 
1. Avoid circumferential irradiation 
2. “point” defined as 0.035cc or less 
3. or one-third of the “native” total organ volume (prior to any resection or volume reducing disease), whichever is greater: 
• 
Exceeding these dose tolerances by more than 2.5% constitutes a minor protocol violation. 
• 
Exceeding these dose tolerances by more than 5% constitutes a major protocol violation. 
 
By protocol prescription, the RT regimen consists of a 5-fraction treatment with doses between 
10-12 Gy per fraction (Bejzak 2015) or 3-fraction treatment with doses of 18-20 Gy per fraction 
to the FDG-PET+ areas delineated as gross tumor volume (GTV). This target volume can be 
translated into an iGTV by including correction for 4D movement, no clinical target margins 
(CTV) are used. An additional 0.5 cm in the axial plane and longitudinal plane (craniocaudal) 
will be added to the GTV to constitute the planning target volume (PTV), while iGTV is 
reconstructed a 0.3cm margin is accepted. Larger margins may be used in cases where greater 
motion of the hemidiaphragm is observed in simulation despite standard maneuvers to diminish 
motion. No (nodal) elective field is given. 
For purposes of dose planning and calculation of monitor units for actual treatment, this protocol 
will require tissue density heterogeneity correction. Successful treatment planning will require 
accomplishment of all the following criteria: 
- 
Maximum dose: The treatment plan should be created such that 100% (60Gy) corresponds to 
the maximum dose delivered to the patient. This point must exist within the PTV. 
- 
Prescription isodose: The prescription isodose surface must be >60% and < 90% of the 
maximum dose (60 Gy) covering the PTV. 
- 
Prescription Isodose Surface Coverage: The prescription isodose surface will be chosen such 
that 95% of the PTV is conformally covered by the prescription isodose surface (PTV 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 36 of 71 
 
 
V95%RX=100%) and 99% of PTV receives a minimum of 90% of the prescription dose 
(PTV V90%RX>99%). 
Fractions should be given within 180 minutes from the end of the GC4711/placebo infusion. A 
minimum of 18 and maximum of 72 hours is permitted between fractions. Additionally, in case of 
machine break-down a 96-hour window is allowed. All fractions must be given within a maximum 
of 10 calendar days (+3 days in the case of a holiday or technical issue). 
 
If SBRT administration is interrupted on any given day due to a machine break-down or other 
unforeseen circumstances, the rest of the treatment or a new SBRT session must be given as soon 
as possible. Rescheduling and SBRT dosing will be determined by the patient’s treating physician 
in accordance with standard of care and covered with extra GC4711/placebo dosing. In case of a 
6th fraction and/or dose of GC4711/Placebo may be given. 
 
Anti-emetic and anti-diarrheal prophylaxis and hematopoietic growth factor use should be 
administered per ASCO guidelines. 
Critical Organ Dose-Volume Limits 
In order to verify dose-volume limits, the organs must be contoured such that appropriate dose 
volume histograms can be generated. Instructions for the contouring of these organs are as follows: 
• Spinal Cord: contoured based on the bony limits of the spinal canal. The spinal cord 
should be contoured starting at least 10 cm above the superior extent of the PTV and 
continuing every CT slice to at least 10 below the inferior extent of the PTV. 
• Esophagus: contoured using mediastinal windowing on CT to correspond to the mucosal, 
submucosa, and all muscular layers out to the fatty adventitia. The esophagus should be 
contoured starting at least 10 cm above the superior extent of the PTV and continuing every 
CT slice to at least 10 below the inferior extent of the PTV. 
• Brachial Plexus: defined ipsilateral brachial plexus originates from the spinal nerves 
exiting the neuroforamina on the involved side from around C5 to T2. However, for the 
purposes of this protocol, only the major trunks of the brachial plexus will be contoured 
using the subclavian and axillary vessels as a surrogate for identifying the location of the 
brachial plexus. This neurovascular complex will be contoured starting proximally at the 
bifurcation of the brachiocephalic trunk into the jugular/subclavian veins (or 
carotid/subclavian arteries) and following along the route of the subclavian vein to the 
axillary vein ending after the neurovascular structures cross the second rib. 
• Heart: contoured along with the pericardial sac. The superior aspect (or base) for purposes 
of contouring will begin at the level of the inferior aspect of the aortic arch (aortopulmonary 
window) and extend inferiorly to the apex of the heart. 
• Trachea and Proximal Bronchial Tree: contoured as two separate structures using 
mediastinal windows on CT to correspond to the mucosal, submucosa and cartilage rings 
and airway channels associated with these structures. For this purpose, the trachea will be 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 37 of 71 
 
 
divided into two sections: the proximal trachea and the distal 2 cm of trachea. The proximal 
trachea will be contoured as one structure, and the distal 2 cm of trachea will be included 
in the structure identified as proximal bronchial tree. Differentiating these structures in this 
fashion will facilitate the eligibility requirement for excluding patients with tumors within 
2 cm of the proximal bronchial tree (see below). 
• Proximal Trachea: Contouring of the proximal trachea should begin at least 10 cm 
superior to the extent of the PTV or 5 cm superior to the carina (whichever is more superior) 
and continue inferiorly to the superior aspect of the proximal bronchial tree (see the 
diagram definitions below). 
• Proximal Bronchial Tree: include the most inferior 2 cm of distal trachea and the 
proximal airways on both sides as indicated in the diagram in Figure 2. The following 
airways will be included according to standard anatomic relationships: the distal 2 cm of 
RTOG 0618 (Timmerman 2018) trachea, the carina, the right and left mainstem bronchi, 
the right and left upper lobe bronchi, the intermedius bronchus, the right middle lobe 
bronchus, the lingular bronchus, and the right and left lower lobe bronchi. Contouring of 
the lobar bronchi will end immediately at the site of a segmental bifurcation. 
• Whole Lung: Planning CT need to cover both entire lung volumes. Both the right and left 
lungs should be contoured as one structure. Contouring should be carried out using 
pulmonary windows. All inflated and collapsed lung should be contoured; however, gross 
tumor (GTV) and trachea/ipsilateral bronchus as defined above should not be included in 
this structure. 
• Skin: defined as the outer 0.5 cm of the body surface. As such it is a rind of uniform 
thickness (0.5 cm) which envelopes the entire body in the axial planes. The cranial and 
caudal surface of the superior and inferior limits of the planning CT should not be 
contoured as skin unless skin is present in these locations (e.g., the scalp on the top of the 
head). 
• All relevant normal tissue structures (e.g. spinal cord, lungs, heart, esophagus, brachial 
plexus, trachea and proximal bronchial tree, skin, etc.) are required in both planning images, 
as well as dose-volume histogram, for further contouring help see RTOG contouring atlas 
(https://www.rtog.org/CoreLab/ContouringAtlases/LungAtlas.aspx). 
 
6.1 
Collection of Concomitant Medications 
Investigators may prescribe concomitant medication or supportive care deemed necessary. All 
medications taken from 30 days prior to dosing through 90 days post discontinuation of SBRT 
should be documented in source records and in the CRF. 
After 3 months post-SBRT, only medications used to treat respiratory disease or late radiation 
toxicities should be recorded through 12 Months post SBRT, including inhalers, steroids, oxygen 
supply, etc. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 38 of 71 
 
 
Additionally, any new anti-cancer therapy given in follow-up should be recorded in the CRF 
through 24-months post-SBRT or until disease progression. 
Supportive care includes anti-emetic prophylaxis, hematopoietic growth factor used as ASCO 
guidelines, systemic antibiotics, hydration to prevent renal damage etc., consistent with local 
standard of practice. 
 
6.2 
Drug Interactions 
In vitro, GC4711 is an inhibitor of CYP2D6. A clinical study of the potential of GC4711 to 
increase the concentration of drugs that are CYP2D6 substrates has not yet been 
conducted. Concomitant use of GC4711 may increase the concentration of drugs that are 
CYP2D6 substrates, which may increase the risk of toxicities of these drugs. Avoid concomitant 
use of GC4711 with CYP2D6 substrates where minimal increases in concentration of the 
CYP2D6 substrate may lead to serious or life-threatening toxicities (substrates with a narrow 
therapeutic range). 
 
Such CYP2D6 substrates (see list below) include certain beta blockers antidepressants, 
antipsychotics and antiarrhythmics. 
 
In addition, concomitant use of GC4711 may decrease the concentration of active metabolites of 
prodrugs that require CYP2D6 for activation. Concomitant use of GC4711 with CYP2D6 
prodrug substrates requiring functional CYP2D6 activity for their clinical benefit (e.g., codeine, 
tramadol, tamoxifen) may decrease their effectiveness. 
Concomitant administration of a CYP2D6-substrate drug concurrent with administration of 
GC4711 should be limited to cases in which the treating investigator has determined that the use 
of the specific CYP2D6-substrate drug is medically necessary. In such cases, the patient should 
be carefully observed for clinical adverse events of the CYP2D6-substrate drug, the dose of 
which may require reduction. 
 
Table 4 below provides some examples of CYP2D6-substrate drugs. See the GC4711 
Investigator's Brochure for additional information. 
 
Table 4 
CYP2D6-substrate drugs 
 
Beta Blockers: 
Antidepressants: 
Antipsychotics: 
Others: 
carvedilol 
S-metoprolol 
propafenone 
timolol 
amitriptyline 
clomipramine 
desipramine 
duloxetine 
fluoxetine 
imipramine 
paroxetine 
haloperidol 
risperidone 
thioridazine 
aripiprazole 
atomoxetine 
codeine dextromethorphan 
doxepine 
flecainide 
mexiletine 
ondansetron 
oxycodone 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 39 of 71 
 
 
 
risperidone 
tamoxifen 
tramadol 
venlafaxine 
 
6.3 
Prohibited Medications 
GC4711 may cause mechanism-related, transient hypotension, or lightheadedness. Because of the 
potential for such mechanism-related toxicities, the following drugs that could precipitate drops in 
blood pressure, should not be taken by patients while receiving GC4711/placebo: 
• Nitrates (sublingual, oral or transdermal nitroglycerin; oral isosorbide mono- or dintitrate) 
 
• Phosphodiesterase type 5 (PDE 5) inhibitors (sildenafil, tadalafil, vardenafil, avanafil). 
• Alpha adrenergic blocking agents prescribed for hypertension, benign prostatic hypertrophy, 
prostate cancer treatment effects, and peripheral artery disease (doxazosin, prazosin, 
terazosin, tamsulosin, alfuzosin, silodosin, phenoxybenzamine, phentolamine). 
• Other drugs that in the judgment of the treating investigator could create a risk of a 
precipitous decrease in blood pressure are prohibited until at least 24 hours after the last dose 
of GC4711 or placebo. 
 
• Approved or investigational anti-cancer therapy (e.g., chemotherapy, immunotherapy, 
targeted therapy, hormone therapy, and biologic therapy) given before disease progression 
other than the protocol regimen without documentation of disease progression 
• Any other investigational therapy not previously approved by the Sponsor 
 
6.4 
Toxicity Management and Infusion Modification 
Anticipated toxicities of GC4711 
Per the Investigator’s Brochure, the following individual adverse events observed in healthy 
volunteer studies are listed and considered “expected” after GC4711 infusions: 
• 
lightheadedness, faintness, or mild decrease in blood pressure 
• 
mild facial tingling 
• 
nausea 
• 
headache 
• 
pain, bruising, or redness at the spot where GC4711 was being given by IV 
• 
pain or discomfort in the arm into which GC4711 was being given by IV 
• 
fatigue 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 40 of 71 
 
 
Toxicity Management/Infusion Modifications 
Any subject who receives treatment on this protocol will be evaluable for toxicity. Each patient 
will be assessed for the development of toxicity according to the Schedule of Assessments (Table 
1). Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse 
Events (CTCAE) Version 5.0. 
Toxicities that will require infusion modification of the GC4711 or placebo administration 
include the following: 
• Grade 2 or greater hypotension occurring within 1 hour of the end of GC4711 or placebo 
infusion 
• Other Grade 3 or greater AEs judged by the investigator to be possibly attributable to the 
study infusion. 
The dose of GC4711/placebo should not be reduced. 
Patients who experience a toxicity noted above during or shortly after the infusion of 
GC4711/placebo should have their infusion times increased to 30 minutes. 
If the toxicity recurs, the infusion time should be increased to 45 minutes, and may be increased 
to 60 minutes if hypotension occurs with a 45-minute infusion. 
If toxicity occurs with a 60-minute infusion, the patient should be discontinued from further 
treatment with GC4711/placebo but should remain on study for all other protocol interventions 
(SBRT) /assessments. 
Anticipated toxicities of SBRT 
Explaining the risk of local high dose RT delivery is important for each individual subject. The 
following anticipated toxicities are used in the informed consent form based on Common 
Toxicity Criteria (CTCAE) version 5 (Table ). 
 
Very likely (80-90%): 
• Fatigue (which generally goes away after the radiation therapy is completed) 
• Abdominal pain, discomfort 
• Nausea, loss of appetite 
 
Less likely (30%): 
• Temporary changes in blood work (decrease in blood counts, increase in liver enzymes), 
without symptoms 
• vomiting (during therapy) 
• diarrhea 
• ulcers 
• Skin irritation, redness, itchiness, discomfort 
• Pain 
• Breathing discomfort, hick-ups 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 41 of 71 
 
 
 
Less likely, but serious (<20%): 
• Gastric, esophagus, small bowel or large bowel irritation/ulceration, bleeding, fistula, 
obstruction, or changes in motility following therapy (may require medications or 
surgery, < 10% permanent changes) 
• Radiation-induced liver disease (RILD, <5%). Classic RILD is a clinical diagnosis of 
anicteric ascites, hepatomegaly and elevation of alkaline phosphatase relative to other 
transaminases that may occur 2 weeks to 3 months following radiation to the liver 
• Non-classic RILD includes elevation of liver enzymes and/or any decline in liver 
function within 12 weeks from start of therapy (~20%). RILD can lead to liver failure 
that could lead to death. There is an increased risk of liver toxicity in subjects with large 
tumors and/ pre-existing liver disease. 
• Permanent thrombocytopenia (<1%); this may lead to bleeding 
• Kidney injury (<1%); this may lead to changes on imaging and more rarely the need for 
medication. 
• Spinal cord injury 
Risk of rare but serious events is more prominent in subjects who did experience toxicities 
during chemotherapy or using co-medications for co-morbidity. Early signs of pain, obstruction 
and anemia need to be closely monitored and ulcers/bleeding treated with proton inhibitors or 
surgically if needed. 
Table 5 
Expected acute and late SBRT toxicities summarized 
 
Acute: 
Late: 
• 
Abdominal pain 
• Liver failure 
• 
Nausea, vomiting 
• Kidney failure 
• 
Diarrhea 
• Abdominal bleeding 
• 
Gastric/duodenal ulcers 
• Bowel stenosis, obstruction, or 
• 
Loss of appetite 
perforation 
• 
Fatigue 
• Persisting thrombopenia, 
• Skin changes 
• Pain 
• Recurrent hick-ups 
• Renal/Liver dysfunction 
• Anemia, thrombopenia, neutropenia 
anemia 
• Spinal cord injury 
 
7 STUDY ASSESSMENTS AND PROCEDURES 
Study procedures and their timing are summarized in the Schedule of Assessments. 
Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 42 of 71 
 
 
Adherence to the study design requirements, including those specified in the SoA is essential and 
required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The investigator will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record reasons for screening failure, as 
applicable. 
Procedures conducted as part of the participant’s routine clinical management (e.g., blood count) 
and obtained before signing of the informed consent form (ICF) may be utilized for screening or 
baseline purposes, provided the procedures met the protocol-specified criteria and were 
performed within the time frame defined in the SoA. 
7.1 
Efficacy Assessments 
Tumor Assessment (RECIST) 
Staging imaging will be performed by CT scan according to the SoA. Tumor Response will be 
evaluated at each time point. Radiographic response will be measured according to RECIST 1.1 
(Eisenhauer 2009). All imaging will be interpreted locally by the investigational site radiologist. 
The same method of imaging used at baseline must be used at each follow up evaluation for 
treatment response. 
The number of subjects exhibiting PR, CR and PR+CR will be reported at Months 6, 12, 18 and 
24. 
 
RECIST 1.1 Tumor Response Evaluation 
Definitions of the criteria used to determine objective tumor response for target lesions 
(Eisenhauer, 2009) 
Complete Response 
(CR): 
Disappearance of all target lesions. Any pathological lymph nodes (whether target 
or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR): 
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters. 
Progressive Disease 
(PD): 
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or 
more new lesions is also considered progression) 
Stable Disease (SD): 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD, taking as reference the smallest sum diameters while on study. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 43 of 71 
 
 
Definitions for Response Evaluation 
Progression-Free Survival 
Progression-free survival (PFS) is defined as the time from the date of registration (Phase 1) or 
randomization (Phase 2), to first occurrence of local and/or regional NSCLC progression, distant 
metastases from NSCLC, second primary tumor, or death due to any cause, whichever occurs 
first. Patients without progression and who did not die are censored at their last evaluable tumor 
response assessment. 
Local and Regional Control 
Local and regional control is defined as the time from registration (Phase 1) or 
randomization (Phase 2), to any local and regional recurrence or progression of NSCLC. 
Local enlargement, marginal failures, involved lobe failure, or local relapse will be 
considered failure events for local control. Regional failure with nodal progression (new 
lesions) in the mediastinum will be a failure event for regional control. Distant metastases 
from the index lung cancer or a second primary tumor are not considered local progression. 
Patients who die with lung cancer, but who do not have documented local progression will 
be considered non-failures for local progression and will be censored on the day of their 
death. Patients who die without progressive lung disease and have no documented local 
progression will be considered non-failures for local progression and will be censored on 
the day of death. 
Overall Survival 
Overall survival (OS) is defined as the time from registration (Phase 1) or randomization (Phase 
2), to death due to any cause. Survival status should be assessed every 6 months following 
progression through 24 months. All subjects who are in the Survival Follow-up Phase and not 
known to have died prior to sponsor requests for additional survival status timepoints may be 
contacted at that time to confirm survival status. Patients who have not died are censored at the 
date last known to be alive. 
Distant Metastasis Rate 
Distant metastasis rate refers to cancer that has spread from the original (primary) tumor to 
distant organs or distant lymph nodes (outside mediastinum). 
7.1 
Safety Assessments 
Planned time points for all safety assessments are provided in the Schedule of Assessments 
(Table 1). 
Physical Examinations 
A complete physical examination will include, at a minimum, assessments of the Cardiovascular, 
Respiratory, Gastrointestinal and Neurological systems. Temperature and weight will also be 
measured and recorded. Height should only be recorded at Screening (Visit 1). The physical 
examination should be performed by a physician or health professional listed on the Form FDA 
1572 and licensed to perform physical examinations. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 44 of 71 
 
 
Vital Signs 
Vital sign measurements prior to each infusion will include pulse rate, respiratory rate, systolic 
and diastolic blood pressure. Pulse and blood pressure readings will be taken after the subject has 
been at rest for 2 minutes before each infusion and after infusion prior to SBRT. Respiratory rate 
does not need to be repeated. 
Electrocardiograms 
A 12-lead ECG recording will be conducted using an ECG machine that automatically calculates 
the heart rate and measures PR, QRS, QT, and QTcF intervals. The recordings should be as close 
as possible to corresponding PK sampling ( +/- 10 minutes from the PK draw) per the SOA. The 
pre- and post-dose ECG should be done in triplicate. 
Pneumonitis Assessment 
The following will be completed for the pneumonitis assessment: 
• NCI-CTCAE 
scale (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CT 
CAE_v5_Quick_Reference_8.5x11.pdf 
• CT of chest with IV contrast, unless contrast is medically contraindicated; evaluate 
for presence of the descriptive items listed in Appendix 4 
• Spirometry including pulse oximetry [SpO2], forced vital capacity [FVC], first 
expiratory volume in the first second [FEV1], and diffusing capacity of the lungs for 
carbon monoxide (DLCO). 
• Medications will be recorded, including inhalers and steroids 
• Hemoglobin (Hb) monitoring (interference if Hb lower than 7 grams per deciliter 
needs repetition of spirometry assessment after Hb correction, e.g., transfusion) 
• Any additional testing should be recorded in the CRF as unscheduled 
 
Lung function 
Clinically, radiation induced pulmonary injury can manifest within weeks to months following 
radiotherapy. However, most cases are reported within the first 8 months. The classic triad of 
symptoms includes dyspnea on exertion, non-productive cough, and hypoxemia, though low- 
grade fevers are also common. Physical exam findings can include pleural friction rub, moist 
rales as well as signs of consolidation. These manifestations may be complicated by the presence 
of pre-existing lung disease such as COPD or emphysema. The incidence of symptomatic 
pneumonitis has dropped with introduction of motion management and other modern RT 
techniques (Jain 2018). The most used grading system is the Common Terminology Criteria for 
Adverse Events (CTCAE) published by the National Cancer Institute: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_refere 
nce_5x7.pdf 
Objectively, the effect of pneumonitis on lung function can be assessed using pulmonary 
function tests (PFTs), a clinical gold standard. Borst, et al. (2005) reported a decrease in first 
expiratory volume in 1 s (FEV1) as early as three months post RT; however, most were observed 
at 6 months. Diffusion capacity of lungs (DLCO) is described as the most prominent PFT 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 45 of 71 
 
 
parameter predictive of and impacted by radiation pneumonitis (Stone 2015, Jain 2018). Our 
primary efficacy measurement of lung function will be prevention of significant falls in DLCO 
by standard pulmonary function testing. DLCO can be affected by different factors, including 
alveolar volume and hematologic assessment, as well as smoking, pre-existent chronic 
obstructive lung disease (COPD), age and medication, including inhalers, oxygen supply and 
steroids. 
In the follow-up portion of this trial, in addition to lung function, hemoglobin will be measured, 
and medication given for respiratory disease and radiation toxicities (See section 7.4), new anti- 
cancer treatments will be recorded through 24 months post SBRT completion, as well as 
smoking and COPD will be monitored throughout 12 months. 
PFTs are not part of standard clinical routine follow-up of radiation therapy but can add 
significant information to radiological and clinical scoring of radiation induced lung injuries. In 
our study, we measure PFTs every six months in parallel to the radiological assessments (Videtic 
2013, Takeda 2013, Ferrero 2015, Vansteenkiste 2014). 
Declines in DLCO from baseline will be scored using the Radiation Therapy Oncology Group 
(RTOG) scale, in which: 
- Grade 0 is <10% decline from baseline; 
- Grade 1 is 10-25% decline from baseline; 
- Grade 2 is >25%-50% decline from baseline; 
- Grade 3 is >50%-75% decline from baseline; 
- Grade 4 is >75% decline from baseline; 
- Grade 5 is death. 
 
7.2 
Adverse Events and Serious Adverse Events 
The definitions of an AE or SAE can be found in 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 46 of 71 
 
 
Appendix 3. The Investigator is responsible for the detection and documentation of events 
meeting the criteria and definition of an AE or SAE as provided in this protocol. Throughout the 
study, AEs will be recorded in the source documents and on the appropriate pages of the CRF 
regardless of whether the AEs are considered related to GC4711/Placebo or SBRT. To avoid 
confusion, the AE should be recorded in standard medical terminology. 
Adverse event(s) will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the study intervention/study (see Section 5.4). 
Time Period and Frequency for Collecting Adverse Events and Serious Adverse 
Events Information 
All adverse events will be collected from the Day 1 dosing through 90 days post-SBRT 
completion to ensure collection of acute toxicities and up to 12 months for late radiation 
toxicities. Please see Section 7.4 for the definition of late radiation toxicities. 
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 47 of 71 
 
 
Appendix 3. The investigator will submit any updated SAE data to the sponsor within 24 hours 
of it being available. Specific SAE reporting instructions are provided in a separate manual. 
Method of Detecting Adverse Events and Serious Adverse Events 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 48 of 71 
 
 
Appendix 3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences. 
Follow-up of Adverse Events and Serious Adverse Events 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is discontinued from the study. Further information on 
follow-up procedures is given in 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 49 of 71 
 
 
Appendix 3. 
Regulatory Reporting Requirements for Serious Adverse Events 
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
intervention under clinical investigation are met. 
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees 
(IEC), and investigators. 
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(SUSAR) according to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary. 
Treatment of Overdose, Misuse, Abuse 
Study drug overdose is any accidental or intentional use of study drug in an amount higher than 
the dose indicated per protocol for a given subject. 
Any study drug overdose during the study should be noted on the study medication eCRF. 
All AEs associated with an overdose should both be entered on the Adverse Event eCRF and 
reported using the procedures detailed in Section 7.2. Reporting of Serious Adverse Events. If 
the AE associated with an overdose does not meet seriousness criteria, it must still be reported 
using the Galera Therapeutics Clinical Trial Report Form for SAEs and in an expedited manner 
but should be noted as non-serious on the form and the Adverse Event eCRF. 
There is currently no specific treatment in the event of an overdose of GC4711. The investigator 
will use clinical judgment and standard supportive care to treat any overdose. 
Adverse events associated with misuse or abuse will be appropriately reported as AEs or SAEs 
and monitored per Section 7.2. 
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the sponsor will review and then file 
it along with the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to 
local requirements. 
 
7.3 
Pregnancy 
The risks of treatment with GC4711 during pregnancy have not been evaluated. Male subjects 
and female subjects of childbearing potential who engage in sexual intercourse should use a 
barrier method of contraception throughout the study and for 30 days (females) or 90 days 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 50 of 71 
 
 
(males) following the last dose of GC4711/Placebo. If a pregnancy is reported, the investigator 
should inform the sponsor within 24 hours of learning of the pregnancy and should follow the 
procedures outlined in Appendix 6. 
 
7.4 
Late Radiotherapy Toxicities 
Late radiotherapy toxicities will be collected as per the Schedule of Assessments. Related, late 
radiation toxicities (Kang 2015) will be collected up to 12 months post SBRT and defined 
using NCI Common Terminology Criteria for Adverse Events (version 5.0).: 
- 
Grade 1-5 Respiratory, thoracic and mediastinal disorders, including rib fractures 
- 
Grade 1-5 esophagus, and 
- 
Grade 3-5 cardiac events 
- 
Grade 3-5 spinal cord/brachial plexopathy and vascular events 
7.5 
Phase 1 Dose-limiting Toxicities 
Safety will be confirmed by the occurrence of dose limiting toxicities (DLTs), which are defined 
(using the NCI-CTC grading scale) as Grade 3-5 AEs occurring from Day 1 to 30 days post SBRT, 
and excluding the following: 
• AEs clearly related to disease progression or intercurrent illness 
• Grade 3 fatigue for 7 days or less, 
• Grade 3 nausea/vomiting or diarrhea for less than 72 hours with adequate antiemetic and 
other supportive care 
• 
Grade 3 or higher electrolyte abnormality that lasts up to 72 hours, is not clinically 
complicated, and resolves spontaneously or responds to conventional medical 
interventions 
• Grade 3 or higher amylase or lipase that is not associated with symptoms or clinical 
manifestations of pancreatitis 
• Hematological grade 3-4 toxicities except for the following: 
o Grade 4 neutropenia lasting >7 days. 
o Grade 3 thrombocytopenia with clinically significant bleeding. 
o Grade 4 anemia and grade 4 thrombocytopenia 
Safety will be considered unacceptable in the Phase 1 portion of the study, if a DLT occurs in 2 
or more of the first 5 subjects. 
In the event of an occurrence of a DLT, the SRC will meet and determine what action should be 
taken with treatment. 
Opening enrollment in the Phase 2 is dependent on the safety outcome (DLT occurrence) in 
Phase 1. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 51 of 71 
 
 
7.6 
Pharmacokinetics (PK) and ECG 
PK sampling will be sought from all patients for GC4711 and its two metabolites, GC4752 and 
GC4757. Blood sampling will be performed along with the ECGs on the days and times 
indicated in the Schedule of Assessments) and outlined below. 
 
PK Draw 
PK draw window 
ECG 
Pre-dose 
- 1 hour from start of 
infusion 
+/- 10 minutes of PK draw 
(triplicate) 
End of Infusion 
+ 10 minutes from EOI 
+/- 10 minutes of PK draw 
(triplicate) 
24-hour Post dose (Phase 
1 only) 
Prior to dosing if delivered 
on next sequential day 
+/- 10 minutes of PK draw 
(single) 
A separate PK Manual will be provided. 
8 STATISTICAL CONSIDERATIONS 
8.1 
Sample size 
In Phase 1 of the study, 5 patients will be treated with GC4711 in combination with SBRT. Dose 
limiting toxicity (DLT) is defined in Section 7.5. Safety is considered acceptable and confirmed 
in the Phase 1 portion of the study, if DLT occurs in no more than one of the first five DLT- 
evaluable patients. 
If acceptable safety in Phase 1 is confirmed, Phase 2 will proceed. Approximately sixty-six (66) 
participants, randomized 1:1 to GC4711 or placebo, will be recruited for the Phase 2 portion to 
achieve 60 evaluable subjects, assuming an approximate 9% drop out rate prior to the 90-day 
timepoint evaluation. 
The primary objective in Phase 2 is to estimate the difference in in-field tumor response between 
GC4711 and placebo through Month 6 following SBRT. Sample size in Phase 2 is selected to 
provide a reasonably precise estimate of the treatment effect as measured by the width of a two- 
sided 90% confidence interval around the difference in in-field tumor response as well as to 
provide other efficacy data that can used in planning future studies. With 30 patients/arm the 
half-width of the 90% confidence interval for the difference will be at most 21.2% % based on 
the large sample confidence interval with limits ± Z.05 √[(p1*(1-p1)/n + p2(1-p2)/m] of the 
point estimate where p1 and p2 are the response rates and n and m the corresponding number of 
patients in each arm. 
8.2 
Randomization/Blinding 
Phase 1: 
The Phase 1 part of the study will be conducted as an open-label investigation. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 52 of 71 
 
 
Phase 2: 
In the Phase 2 of the study, all subjects, investigators, clinical study site personnel and the 
blinded study monitor will be blinded to patient treatment assignment. 
The dispensing Site Pharmacists are unblinded. An unblinded Study Monitor will be assigned to 
the study for confirming drug accountability and monitoring at the site’s pharmacy. The 
Unblinded Pharmacist should take every precaution to prepare the study treatment in a blinded 
fashion and out of site from the Blinded site clinical staff. The Blinded Clinical Staff should be 
mindful of the steps in place to maintain the blind. 
Treatment assignment for Phase 2 subjects should remain blinded to subjects, investigators, and 
clinical site staff until analyses of the primary and secondary safety and efficacy results of the 
study have been performed on the final, locked data through the end of post-SBRT follow-up for 
all subjects. 
Only in the case of an emergency, when knowledge of the investigational product is essential for 
the clinical management or welfare of the subject, may the Investigator unblind an individual 
subject’s treatment assignment prior to the completion of the primary and secondary safety and 
efficacy analyses. The Investigator will, whenever possible, discuss options with the Medical 
Monitor or appropriate Sponsor/CRO study personnel before unblinding. If the blind is broken 
for any reason and the Investigator is unable to contact the Sponsor prior to unblinding, the 
Investigator must notify the Sponsor/CRO as soon as possible following the unblinding incident 
without revealing the subject’s study treatment assignment, unless the information is important 
to the safety of subjects remaining in the study. 
Randomization codes are generated and assigned using a Randomization and Trial Supply 
Management (RTSM) system. Electronic access to the randomization codes will be granted for 
unblinded pharmacy team members and unblinded CRAs. 
8.3 
Populations for Analyses 
The Phase 1 population will include all subjects who receive at least one dose of GC4711. The 
DLT evaluable population includes all patients in the Phase 1 population who have received all 
five GC4711 doses, are followed for 30 days post SBRT and were DLT free or experienced a 
DLT. The Phase 2 intent-to-treat population includes all subjects randomized and is used in 
disposition. Safety and efficacy analyses for Phase 2 will be performed on a modified intent-to- 
treat population that includes all randomized subjects who receive at least one dose of GC4711 
or placebo. 
8.4 
Subject Disposition 
The number of subjects included in each study population will be summarized by treatment 
group. Subjects excluded from the intent-to-treat population will be listed by randomized 
treatment group. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 53 of 71 
 
 
The number and percentage of subjects who complete or who prematurely discontinue during the 
treatment periods will be presented. Screen failures (i.e., screened but not randomized subjects) 
and the associated failure reasons will be tabulated overall. Reasons for premature 
discontinuation from the treatment period as recorded on the termination page of the eCRF will 
be summarized (number and percentage) by treatment group for all randomized/registered 
subjects. 
8.5 
Statistical Analyses 
The statistical analysis plan will be finalized prior to database lock and will include a more 
detailed description of the statistical analyses described in this section. Should the statistical 
analysis plan and the protocol differ with respect to analytic conventions, the statistical analysis 
plan supersedes the protocol. Given the study has not been powered for formal hypotheses 
testing, all P-values should be considered descriptive in nature. As such no alpha adjustment for 
multiple testing is planned. 
All time to event endpoints will be measured from date registration (Phase 1) or randomization 
(Phase 2). 
Primary Endpoints: 
Phase 1: DLT defined in Section 7.5. 
Phase 2: The difference in in-field tumor response between GC4711 and placebo through Month 
6 following SBRT will be estimated, and a two-sided 90% confidence interval constructed 
around the difference using the large sample confidence interval with limits ± Z.05 √[(p1*(1- 
p1)/n + p2(1-p2)/m] of the point estimate where p1 and p2 are the response rates and n and m the 
corresponding number of patients in each arm. In addition, a Fisher’s Exact test will be 
performed but should be considered descriptive in nature. Phase 2: Percent reduction of in-field 
tumor response at Month 6 compared to baseline. 
Secondary Efficacy Endpoints: 
Phase 1: All Phase 1 efficacy endpoints will be summarized descriptively. 
Phase 2: Response rate (PR+CR at any time during the study) per RECIST 1.1 will be compared 
using the same methodology as the primary endpoint. 
In-field tumor response at Months 6, 12, 18 and 24 will be compared for the two treatment arms 
using a t-test at each timepoint and corresponding two-sided 90% confidence intervals 
constructed about the difference. The maximum reduction for each patient observed at any time 
will be analyzed similarly. 
Progression-free survival (PFS) will be compared using a hazard ratio along with the associated 
2-sided 90% confidence interval, using an un-stratified Cox’s proportional hazard model and 
further characterized by Kaplan-Meir curves as well as the median and survival probability at 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 54 of 71 
 
 
representative times (e.g. at 2, 4, 6, 4 etc. months). A log-rank test comparing treatment arms 
based on the score statistic from the Cox regression will also be provided. Patients who have not 
progressed of died will be censored at their last evaluable response assessment. 
Overall Survival (OS) as well as duration of local and regional control will be analyzed using the 
same approach as PFS. For OS, patients who have not died as of the time of analysis will be 
censored the date last known to be alive. For duration of local and regional control, local 
enlargement, marginal failures, involved lobe failure, or local relapse will be considered failure 
events for local control. Regional failure with nodal progression (new lesions) in the 
mediastinum will be a failure event for regional control. Distant metastases from the index lung 
cancer or a second primary tumor are not considered local progression. Patients who die with 
lung cancer, but who do not have documented local progression will be considered non-failures 
for local progression and will be censored on the day of their death. Patients who die without 
progressive lung disease and have no documented local progression will be considered non- 
failures for local progression and will be censored on the day of death. 
Distant-metastases rate will be summarized descriptively. 
Exploratory Endpoints 
All safety endpoints will be summarized descriptively including mean and mean change from 
baseline for continuous endpoints and n and percent for categorical endpoints. 
 
8.6 
Safety Review Committee (SRC) 
In the Phase 1 portion of the study, safety will be reviewed by a Safety Review Committee 
(SRC) consisting of the Medical Monitor, the Principal Investigators, and additional designees 
by the Sponsor or the site Principal Investigators. After Phase 1, safety will be reviewed by the 
safety review committee (SRC) before proceeding to Phase 2. 
 
In Phase 2, the Sponsor will perform routine reviews of the safety data at an interval no less than 
quarterly and after the 20th randomized subject reaches the 30-day follow up timepoint, 
whichever occurs first. 
 
8.7 
Interim Analysis 
During the Phase 2 portion of the study, an unblinded interim analysis will be performed after 
6‑ month follow-up data are available for the first 20 randomized subjects (i.e., roughly 30 
percent of the planned enrollment of 66 subjects in Phase 2), for the purposes of assessing 
preliminary efficacy. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 55 of 71 
 
 
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
- 
Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines 
- 
Applicable International Council for/Conference on Harmonization (ICH) Good Clinical 
Practice (GCP) Guidelines 
- 
Applicable laws and regulations 
The protocol, protocol amendments, ICF, Investigator’s Brochure, and other relevant documents 
(e.g, participant recruitment advertisements) must be submitted to an Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) by the investigator and reviewed and approved by 
the IRB/IEC before the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants. 
The investigator will be responsible for the following: 
- 
Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by the 
IRB/IEC 
- 
Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures 
- 
Providing oversight of the conduct of the study at the site and adherence to requirements of 
21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations 
 
 
Financial Disclosure 
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information, as requested, to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 56 of 71 
 
 
Informed Consent Process 
In accordance with regulatory and local IRB/IEC/REB requirements, before study procedures are 
performed, subjects will be informed about the study and required to sign the IRB/IEC/REB 
approved ICF. This form will be signed after adequate explanation of the aims, methods, 
objective and potential hazards of the study and prior to undertaking any study-related 
procedures. The Sponsor or its designee will provide an ICF template to the investigator. The 
Sponsor or its designee must approve changes to the ICF template prior to submission to the 
IRB/IEC/REB. Informed consent will be obtained according to the applicable IRB/IEC/REB 
requirements. No patient is to be screened or treated until an ICF, written in a language in which 
the patient is fluent, has been obtained. The signed ICF will be retained with the study records. 
Each patient will also be given a copy of his/her signed ICF. 
Data Protection 
Participants will be assigned a unique identifier by the sponsor. Any participant records or 
datasets that are transferred to the sponsor will contain the identifier only; participant names or 
any information that would make the participant identifiable will not be transferred. 
The participant must be informed that his/her personal study-related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent. 
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
Data Quality Assurance 
All participant data relating to the study will be recorded on printed or eCRFs unless transmitted 
to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for 
verifying that data entries are accurate and correct by physically or electronically signing the 
CRF. 
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections, and provide direct access to source data documents. 
The sponsor or designee is responsible for the data management of this study including quality 
checking of the data. 
The sponsor assumes accountability for actions delegated to other individuals (eg, Contract 
Research Organizations). 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 57 of 71 
 
 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements. 
Source Documents 
Source documents include but are not limited to original documents, data and records such as 
hospital/ medical records (including electronic health records), clinic charts, lab results, subject 
diaries, data recorded in automated instruments, microfilm or magnetic media, and pharmacy 
records, etc. At a minimum, all data required to be collected by the protocol should have 
supporting source documentation for entries in the eCRF, unless the protocol specifies that data 
can be recorded directly on/in the eCRF or other device. 
Study and Site Start and Closure 
The study start date is the date on which the clinical study will be open for recruitment of 
participants. 
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to: 
- 
Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the sponsor's procedures, or GCP guidelines 
- 
Inadequate recruitment of participants by the investigator 
- 
Discontinuation of further study intervention development 
If the study is prematurely terminated or suspended, the sponsor will promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The investigator will promptly inform the subject and must ensure 
appropriate subject therapy and/or follow-up 
Publication Policy 
- 
The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before 
submission. This allows the sponsor to protect proprietary information and to provide 
comments. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 58 of 71 
 
 
- 
The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In this 
case, a coordinating investigator will be designated by mutual agreement. 
- 
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 59 of 71 
 
 
Appendix 2: Clinical Laboratory Tests 
The tests detailed in Table will be performed by the local laboratory per the SoA. Abnormal 
clinically significant local laboratory results collected outside of the protocol should be captured 
as Adverse Events. 
Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 
of the protocol. Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations. 
Table 5 Protocol-Required Safety Laboratory Assessments 
 
Hematology/CBC 
Biochemistry 
Other 
ANC 
Blood urea nitrogen (BUN) 
INR/PTT (SCRN only) 
Hemoglobin 
Creatinine 
Hematocrit 
Creatinine clearance 
Red blood cell (RBC) 
Count 
Glucose 
Potassium 
White blood cell (WBC) 
count 
Sodium 
Calcium 
Platelet Count 
Chloride 
WBC Differential 
CO2 
Inorganic phosphate 
Aspartate Aminotransferase 
(AST) 
Alanine Aminotransferase (ALT) 
Gamma-glutamyl transferase 
(GGT) 
Total bilirubin (direct bilirubin 
reflex if elevated) 
Albumin 
Alkaline phosphatase (ALP) 
Uric acid 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 60 of 71 
 
 
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
Definition of Adverse Event 
 
AE Definition 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product. 
- 
 
Events Meeting the AE Definition 
- 
Any abnormal laboratory test results (such as hematology, clinical chemistry) or other 
safety assessments (e.g., ECG, radiological scans, vital signs measurements), including 
those that worsen from baseline, considered clinically significant in the medical and 
scientific judgment of the investigator (i.e., not related to progression of underlying 
disease). 
- 
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
- 
Any new condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study. 
- 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction, including 
investigational product with a concomitant mediation. 
- 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae. 
- 
For situations when an AE or SAE is due to NSCLC report all known signs and symptoms. 
Death due to disease progression in the absence of signs and symptoms should be reported 
as the primary tumor type (e.g., metastatic NSCLC). Note: The term “disease progression” 
should not be used to describe the DRE or AE. 
 
Events NOT Meeting the AE Definition 
-  Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 61 of 71 
 
 
 
- 
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition. 
- 
Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to 
the procedure is the AE. 
- 
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
- 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
 
Definition of Serious Adverse Event 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease). 
 
An SAE is defined as any untoward medical occurrence that, at any dose: 
• Results in death 
• Immediately life threatening 
The term 'life threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe. 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the participant has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment that 
would not have been appropriate in the physician’s office or outpatient setting. Complications 
that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills 
any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” 
occurred or was necessary, the AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
• Results in persistent disability/incapacity 
- 
The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions. 
- 
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) that may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption. 
• Is a congenital anomaly/birth defect 
• Other medically important serious event: 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 62 of 71 
 
 
 
- 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These events should usually be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that 
do not result in hospitalization, or development of drug dependency or drug abuse. 
 
Recording and Follow-Up of Adverse Events and/or Serious Adverse Events 
 
AE and SAE Recording 
- 
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event. 
- 
The investigator will then record all relevant AE/SAE information in the CRF. 
- 
It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to Galera Therapeutics in lieu of completion of the AE/SAE CRF page. 
- 
There may be instances when copies of medical records for certain cases are requested by 
Galera Therapeutics. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to Galera Therapeutics. 
- 
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE. 
- 
The investigator must assign the following AE attributes: 
o AE diagnosis or syndrome(s), if known (if not known, signs or symptoms); 
o Dates of onset and resolution (if resolved); 
o Severity (or toxicity defined below); 
o Assessment of relatedness to GC4711, SBRT; and 
o Action taken. 
Severity/Grading of Adverse Events 
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study using NCI CTCAE grading scale, Version 5.0. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 63 of 71 
 
 
 
Assessment of Causality 
- 
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE. 
- 
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled 
out. 
- 
The investigator will use clinical judgment to determine the relationship. 
- 
Alternative causes, such as underlying disease(s), concomitant therapy/treatments, and 
other risk factors, as well as the temporal relationship of the event to study intervention 
administration, will be considered and investigated. 
- 
The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment. 
- 
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality. 
- 
There may be situations in which an SAE has occurred, and the investigator has minimal 
information to include in the initial report to Galera Therapeutics. However, it is very 
important that the investigator always makes an assessment of causality for every 
event before the initial transmission of the SAE data to Galera Therapeutics. 
- 
The investigator may change his/her opinion of causality in light of follow-up information 
and send an SAE follow-up report with the updated causality assessment. 
- 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AEs and SAEs 
- 
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Galera 
Therapeutics to elucidate the nature and/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
- 
New or updated information will be recorded in the originally completed CRF. 
- 
The investigator will submit any updated SAE data to Galera Therapeutics within 24 hours 
of receipt of the information. 
Reporting of SAEs 
 
SAE Reporting to IQVIA Safety 
All SAEs should be submitted in compliance with the reporting requirements and timelines 
per the SAE Report Form Completion Guidelines. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 64 of 71 
 
 
Appendix 4: Relationship Between National Cancer Institute – Common 
Terminology Criteria for Adverse Events, Version 5.0 and Radiographic 
Pneumonitis/Fibrosis Criteria (Kimura IJROB 2006) 
Subjects will be evaluated radiographically for presence of the descripted items listed in the 
table below. The Grade and p-value columns are included only as a reference to the 
relationship between CTCAE grading of pneumonitis and the presence of the descriptors and do 
not need to be considered when collecting subject data. 
 
Grade 1* Grade 2* Grade 3* 
Total 
p value†† 
Acute radiation pneumonitis 
Diffuse consolidation 
3 
11 
2 
16 
0.000675 
Patchy consolidation and GGO 
6 
2 
0 
8 
0.175 
Diffuse GGO 
4 
2 
0 
6 
0.479 
Patchy GGO 
0 
1 
0 
1 
0.286 
No evidence of increased density 
12 
3 
1 
16 
0.0314 
Radiation fibrosis 
Modified conventional pattern 
12 
14 
1 
27 
0.0394 
Mass-like pattern 
4 
3 
2 
9 
0.559 
Scar-like pattern 
9 
2 
0 
11 
0.0297 
Total 
25 
19 
3 
47 
 
Abbreviation: GGO = ground-glass opacity. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 65 of 71 
 
 
Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information 
Definitions: 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below). 
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP 
- 
Premenarchal 
- 
Premenopausal female with 1 of the following: 
- 
Documented hysterectomy 
- 
Documented bilateral salpingectomy 
- 
Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the above, 
(eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to 
determining study entry. 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
- 
Postmenopausal female 
- 
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause. 
Male participants with partners who become pregnant 
The investigator will attempt to collect pregnancy information on any male participant’s female 
partner who becomes pregnant while the male participant is in this study. This applies only to 
male participants who receive GC4711. 
After obtaining the necessary signed informed consent from the pregnant female partner directly, 
the investigator will record pregnancy information on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be 
followed to determine the outcome of the pregnancy. Information on the status of the mother and 
child will be forwarded to the sponsor. Generally, the follow-up will be no longer than 6 to 
8 weeks following the estimated delivery date. Any termination of the pregnancy will be 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 66 of 71 
 
 
reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure. 
Female Participants who become pregnant/breastfeed 
The investigator will collect pregnancy information on any female participant who becomes 
pregnant or breastfeeds during treatment and 30 days after GC4711/placebo. Information will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours of learning of a 
participant's pregnancy. 
The participant will be followed to determine the outcome of the pregnancy. The investigator 
will collect follow-up information on the participant and the neonate, and the information will be 
forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks 
beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of 
fetal status (presence or absence of anomalies) or indication for the procedure. 
A spontaneous abortion (occurring at < 22 weeks gestational age) or still birth (occurring at > 22 
weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any female participant who becomes pregnant while participating in the study will discontinue 
study intervention. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 67 of 71 
 
 
 
Appendix 6: Abbreviations 
AE 
adverse event 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
ANC 
absolute neutrophil count 
AST 
aspartate aminotransferase 
BED 
biologically equivalent (total) dose 
BMI 
body mass index 
BP 
blood pressure 
BUN 
blood urea nitrogen 
CBC 
complete blood count 
CFR 
Code of Federal Regulation 
CI 
confidence interval 
CIOMS 
Council for International Organizations of Medical Sciences 
COPD 
chronic obstructive pulmonary disease 
CRF 
Case Report Form 
CSR 
Clinical Study Report 
CT 
computed tomography 
CTCAE 
common terminology criteria for adverse events 
DLCO 
diffusion capacity of lung for carbon monoxide 
DLT 
dose limiting toxicity 
ECG 
electrocardiogram 
ECOG PS 
eastern cooperative oncology group performance status 
eCRF 
electronic Case Report Form 
FDA 
Food and Drug Administration 
PET/CT 
Positron emission tomography combined with CT scan 
FEV1 
forced expiratory volume in 1 second 
FVC 
forced vital capacity 
GCP 
Good Clinical Practice 
GGT 
gamma-glutamyl transferase 
GLP 
Good Laboratory Practice 
HIPAA 
Health Insurance Portability and Accountability Act 
Hgb 
hemoglobin 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 68 of 71 
 
 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Council for/Conference on Harmonisation 
IEC 
Independent Ethics Committees 
IRB 
Institutional Review Boards 
IV 
intravenous 
NCI 
National Cancer Institute 
NOAEL 
no observed adverse effect level 
NSCLC 
non-small cell lung cancer 
OS 
overall survival 
PET 
positron emission tomography 
PFS 
progression-free survival 
PFT 
pulmonary function test 
PK 
Pharmacokinetic(s) 
PTV 
planning treatment volume 
RBC 
red blood cell 
RECIST 
response evaluation criteria in solid tumors 
RT 
radiation therapy 
RTOG 
radiation therapy oncology group 
RTSM 
Randomization and Trial Supply Management 
SAE 
serious adverse event 
SABR 
stereotactic ablative body radiation therapy 
SBRT 
stereotactic body radiation therapy 
SOA 
schedule of activities 
SOD 
superoxide dismutase 
SOM 
severe oral mucositis 
SRC 
safety review committee 
SUSAR 
suspected unexpected serious adverse reactions 
ULN 
upper normal limit 
WBC 
white blood cell 
WOCBP 
woman of childbearing potential 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 69 of 71 
 
 
 
Appendix 7: References 
Anderson CM, Lee CM, Saunders DP, Curtis A, et al Phase IIb, Randomized, Double-Blind 
Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent 
Radiotherapy and Cisplatin For Head and Neck Cancer. J Clin Oncol. 2019 Dec 1;37(34):3256- 
3265. doi: 10.1200/JCO.19.01507. Epub 2019 Oct 16. 
Baumann P, Nyman J, Hoyer M, Wennberg B, et al Outcome in a prospective phase II trial of 
medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body 
radiotherapy.J Clin Oncol. 2009 Jul 10;27(20):3290-6. doi: 10.1200/JCO.2008.21.5681. Epub 
2009 May 4. 
Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body 
radiotherapy schedule for centrally located non-small cell lung cancer: NRG 
Oncology/RTOG0813 trial. J Clin Oncol 2019;37(15):1316-1325. 
Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV Pulmonary function changes 
after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int 
J Radiat Oncol Biol Phys. 2005 Jul 1; 62(3):639-44. 
Böhm B, Heinzelmann S, Motz M, Bauer G. Extracellular localization of catalase is associated 
with the transformed state of malignant cells. Biol Chem. 2015;396(12):1339‑ 1356. 
doi:10.1515/hsz-2014-0234 
Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung 
cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 
1996;32A(7):1135‑ 1141. doi:10.1016/0959-8049(95)00664-8 
Chang J.H, Poon I.Erler D.et al The safety and effectiveness of stereotactic body radiotherapy for 
central versus ultracentral lung tumors.Radiother Oncol. 2018; 129: 277-283 
Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for 
treatment of central and ultra-central lung tumors. Lung Cancer 2015;89:50-6. 
Corso CD, Park HS, Moreno AC, Kim AW, Yu JB, Husain ZA, Decker RH. Stage I Lung SBRT 
Clinical Practice Patterns. Am J Clin Oncol. 2017 Aug;40(4):358-361. doi: 
10.1097/COC.0000000000000162. PMID: 25503436. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247. 
Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung 
Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464‑ 1472. 
doi:10.6004/jnccn.2019.0059 
Fakiris, AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic Body Radiation Therapy for Early- 
Stage Non–Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II Study. Int J 
Radiat Oncol Bio Phys 2009;75(3):677-682. 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 70 of 71 
 
 
Ferrero C, Badellino S, Filippi AR, Focaraccio L, Giaj Levra M, Levis M, Moretto F, Torchio R, 
Ricardi U, Novello S. Pulmonary function and quality of life after VMAT-based stereotactic 
ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer. 2015 
Sep;89(3):350-6. doi: 10.1016/j.lungcan.2015.06.019. Epub 2015 Jun 26. PMID: 26164208 
Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J Biol 
Chem. 1997;272(30):18515‑ 18517. doi:10.1074/jbc.272.30.18515 
Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and 
diseases. Antioxid Redox Signal. 2011;15(6):1583-1606. 
Greenberger, J. S., Epperly, M. W. (2007) Review. Antioxidant gene therapeutic approaches to 
normal tissue radioprotection and tumor radiosensitization. In Vivo, 21(2), 141-6. 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R 
eference_8.5x11.pdf (Accessed on March 09, 2018). 
Huang K. Dahele M. Senan S.et al. Radiographic changes after lung stereotactic ablative 
radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the 
literature. Radiother Oncol. 2012; 102: 335-342 
Jain V, Berman AT. Radiation Pneumonitis: Old Problem, New Tricks. Cancers (Basel). 
2018;10(7):222. Published 2018 Jul 3. doi:10.3390/cancers10070222 
Kang KH, Okoye CC, Patel RB, et al. Complications from Stereotactic Body Radiotherapy for 
Lung Cancer. Cancers (Basel). 2015 Jun 15;7(2):981-1004. doi: 10.3390/cancers7020820. 
Review. 
Kasten TP, Settle SL, Misko TP, et al. Potentiation of nitric oxide-mediated vascular relaxation 
by SC52608, a superoxide dismutase mimic. Proc Soc Exp Biol Med. 1995;208(2):170-177. 
Kimura T, Matsuura K, Murakami Y, et al. CT appearance of radiation injury of the lung and 
clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients 
with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol 
Phys. 2006 Oct 1;66(2):483-91. Epub 2006 Aug 14. 
Larici AR, del Ciello A, Maggi F, et al. Lung abnormalities at multimodality imaging after 
radiation therapy for non-small cell lung cancer. Radiographics 2011;31(3):771-789. 
Lee P, Loo BW Jr, Biswas T, Ding GX, El Naqa IM, Jackson A, Kong FM, LaCouture T, Miften 
M, Solberg T, Tome WA, Tai A, Yorke E, Li XA. Local Control After Stereotactic Body 
Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 
May 1;110(1):160-171. doi: 10.1016/j.ijrobp.2019.03.045. Epub 2019 Apr 5. PMID: 30954520. 
Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes 
HR, Timmerman RD. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev 
Clin Oncol. 2010 Jan;7(1):44-54. doi: 10.1038/nrclinonc.2009.188. Epub 2009 Dec 8. Erratum 
in: Nat Rev Clin Oncol. 2010 Aug;7(8):422. Dosage error in article text. PMID: 19997074. 
Lu C, Lei Z, Wu H, Lu H (2018) Evaluating risk factors of radiation pneumonitis after 
stereotactic body radiation therapy in lung tumor: Meta-analysis of 9 observational studies. PLoS 
ONE 13(12): e0208637.https://doi.org/10.1371/journal.pone.0208637 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 71 of 71 
 
 
Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudo-progression from true 
progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019;9(8):1546- 
1553. Published 2019 Aug 1. 
 
Mapuskar KA, Anderson CM, Spitz DR, Batinic-Haberle I, Allen BG, R EO-D. Utilizing 
Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting 
Normal Tissues. Semin Radiat Oncol. 2019;29(1):72-80. 
Miller AF. Superoxide dismutases: ancient enzymes and new insights. FEBS Lett. 
2012;586(5):585-595. 
Mohamad O, Diaz de Leon A, Schroeder S, et al. Safety and efficacy of concurrent immune 
checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology. 
2018;7(7):e1440168. https://doi.org/10.1080/2162402X.2018.1440168 
Murphy C, Fey EG, Watkins BA, Wong V, Rothstein D, Sonis ST. Efficacy of superoxide 
dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Can 
Res 2008;14:4292-97. 
Oberley, T. D., Oberley, L. W. (1997) Antioxidant enzyme levels in cancer. Histol Histopathol, 
12(2), 525-35 
Palma DA, Senan S, Tsujino K, et al Predicting Radiation Pneumonitis after Chemoradiotherapy 
for Lung Cancer: An International Individual Patient Data Meta analysis Int J Radiat Oncol Biol 
Phys. 2013 February 1; 85(2): 444–450. doi:10.1016/j.ijrobp.2012.04.043. 
Peterson J, Niles C, Patel A, et al. Stereotactic Body Radiotherapy for Large (>5 cm) Non-Small 
Cell Lung Cancer. Clin Lung Can 2016;18(4):396-400. 
Prezzano KM, Ma SJ, Hermann GM, et al Stereotactic body radiation therapy for non-small cell 
lung cancer: A review. World J Clin Oncol. 2019 Jan 10; 10(1): 14–27. 
Román A, Perez-Rozos A, Otero A, Jodar C, García-Ríos I, Lupiañez-Perez Y, Antonio Medina 
J, Gomez-Millan J. Efficacy and safety of a simplified SBRT regimen for central and peripheral 
lung tumours. Clin Transl Oncol. 2020 Jan;22(1):144-150. doi: 10.1007/s12094-019-02119-6. 
Epub 2019 May 2. PMID: 31049820. 
Sishc BJ, Polsdofer EM, Bloom DA, et al. The radioprotector GC4419 ameliorates radiation 
induced lung fibrosis while enhancing the response of non-small cell lung cancer tumors to high 
dose per fraction radiation exposures [abstract]. In: Proceedings of the American Association for 
Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia 
(PA):AACR; Cancer Res 2018;78(13 Suppl):Abstract# 667. 
Sishc BJ, Polsdofer EM, Zhang Y, et al. The radioprotector GC4419 enhances the response of 
squamous cell carcinoma of the head and neck tumors to ionizing radiation and enhances 
radioimmune therapy. [abstract]. In: Proceedings of the American Association for Cancer 
Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR 
2019;Abstract #2922. 
Stanic S, Paulus R, Timmerman RD, et al. No clinically significant changes in pulmonary 
function following stereotactic body radiation therapy for early- stage peripheral non-small cell 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 72 of 71 
 
 
lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88(5):1092-1099. 
doi:10.1016/j.ijrobp.2013.12.050 
Stephans KL, Woody NM, Reddy CA, et al. Tumor Control and Toxicity for Common 
Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell 
Lung Cancer.Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):462-469. doi: 
10.1016/j.ijrobp.2017.10.037. Epub 2017 Oct 28. 
Stone B, Mangona VS, Johnson MD et.al. Changes in pulmonary function following image- 
guided stereotactic lung radiotherapy. J Thorac Oncol. 2015;10: 1762–1769 
Tadasuke Si, Shoko N, Tomoyuki N, et al Clinical characteristics of nivolumab-induced 
radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real-world 
analysis of 669 patients. Journal of Clinical Oncology 2020 38:5_suppl, 88-88 
Takeda A, Enomoto T, Sanuki N, Handa H, Aoki Y, Oku Y, Kunieda E. Reassessment of 
declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest. 2013 
Jan;143(1):130-137. doi: 10.1378/chest.12-0207. PMID: 22722234. 
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, 
Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central 
tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early- 
stage lung cancer.J Clin Oncol. 2006 Oct 20;24(30):4833-9. 
Timmerman R, Paulus R, Galvin J, et al. Stereotactic Body Radiation Therapy for Inoperable 
Early Stage Lung Cancer. JAMA. 2010;303(11):1070–1076. doi:10.1001/jama.2010.261 
Timmerman RD, Hu C, Michalski JM, et al. Long-term Results of Stereotactic Body Radiation 
Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer. JAMA Oncol. 
2018;4(9):1287–1288. doi:10.1001/jamaoncol.2018.1258 
Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van 
Schil P, Veronesi G, Stahel R, Peters S, Felip E; Panel Members. 2nd ESMO Consensus 
Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, 
treatment and follow-up. Ann Oncol. 2014 Aug;25(8):1462-74. doi: 10.1093/annonc/mdu089. 
Epub 2014 Feb 20. PMID: 24562446. 
Videtic GM, Reddy CA, Sorenson L. A prospective study of quality of life including fatigue and 
pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage 
lung cancer. Support Care Cancer. 2013 Jan;21(1):211-8. doi: 10.1007/s00520-012-1513-9. Epub 
2012 Jun 2. 
Woody NM, Stephans KL, Marwaha G, et al. Stereotactic Body Radiation Therapy for Non- 
Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy. Int J Radiat Oncol 
Biol Phys 2015;92(2):325-331. 
Yamashita A, Takahashi W, Haga A, Nakagawa K. Radiation pneumonitis after stereotactic 
radiation therapy for lung cancer World J Radiol 2014 September 28; 6(9): 708-715 

Compound: GC4711 
Protocol GTI-4711-101 
Amendment 4.0, 18Apr2022 
Galera Therapeutics, Inc. 
Page 73 of 71 
 
 
Zhao J, Yorke ED, Li L, Kavanagh BD, et al. Simple Factors Associated With Radiation- 
Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled 
Analysis of 88 Studies. Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1357-1366.